Synergy Club


Al-Hilal Drug Store is located in Amman, Jordan. Company is working in Pharmacies business activities.  We are involved in the registration, importation, marketing, sales and distribution of pharmaceutical products, medical equipment, and medical devices items.

A. Menarini Asia-Pacific is the regional hub of leading Italian pharmaceutical company Menarini Group. We combine the strengths of our global resources with local customer insights to bring the best medical innovations to hospitals and healthcare providers.\r\nDirectly present in 13 Asia-Pacific markets, we manage an extensive portfolio of proprietary healthcare brands and licensed brands from some of the world’s leading biotech companies. From R&D through to manufacturing, regulatory approvals and commercialization – we are there every step of the way.

AAA-PHARMA GmbH Looking for in-licensing opportunities of Rx Generics backed by EU-GMP Sites – AAA-Pharma is successful on the German Tender market & is currently pursuing an aggressive internationalization strategy, as part of Wörwag Pharma, with market presence in 35+ countries, including Eastern Europe, Russia, the Baltics, Central Asia, Asia, and Latin America.

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 109,000 colleagues serve people in more than 160 countries.

The ABC Farmaceutici group was born in 1925, in Italy. The international operation, under the division ABC International Pharma, was established in 1999, so we can claim more than 20 years of experience in foreign businesses. Thanks to our long history and knowledge, we are present in more than 40 countries all over the world, with our own medicines, medical device, food supplements and dermo-cosmetic. The production site is located in North West of Italy (Ivrea) and combines the highest levels of technological innovation, together with our long tradition and history. Manufacturing facility is complying with the latest GMP recommendations and it extends its business to an increasing contract manufacturing activity, thanks to the collaboration with main pharmaceutical multinational Companies. Moreover we are firmly engaged in the development of new pharmaceutical products and forms, provided with updated CTD dossiers. Over our long history we filed 13 international patents. Our product list includes ethical, branded, generics, medical devices, OTC food supplement and dermo-cosmetics products and part of the active ingredient utilised in the production of pharmaceutical dosages, are manufactured by our API Division (in activities since 1940). We launched a new interesting medical device, very effective in the treatment of atopic dermatitis, seborrheic dermatitis, contact erythema (irritant and allergic), psoriasis and scleroderma. We are interested both in licensing-out and -in. As well we are open to evaluate new product development and contract manufacturing activities in our premises.

Abdi İbrahim, Turkish pharmaceutical industry leader, was founded in 1912 in Küçükmustafapaşa, Istanbul at a small pharmacy, by Pharmacist Abdi İbrahim Bey who had started the “healing” journey. Abdi İbrahim has the largest product portfolio in the sector, exceeding 200 brands and more than 450 products by developing its own products as well as working with 30 licensors. With a powerful vision, dynamic structure and contemporary outlook, Abdi İbrahim has been the leader of Turkey’s Pharmaceutical Industry since 2002. Today, Abdi İbrahim, which operates in 12 countries outside Turkey, exports to more than 60 countries ranging from Canada to European Union member states, from North Africa to Asia and creates the highest employment with nearly 4.500 qualified employees in the Turkish pharmaceutical industry. The company also comes to the fore with its marketing and sales team, which is the largest in the industry. Abdi İbrahim, having the first accredited R&D center in the industry, is a role model with its technological equipment and architecture as well as R&D processes in healing the future. Abdi Ibrahim has an R&D Center, production facility for chemical products, Turkey’s largest biotechnological manufacturing facility AbdiBio and hormone production area, ophthalmology production area which will be operational in 2019 and Sterile Injectable & Oncology production facility which will be operational in 2021 in Istanbul Esenyurt production complex. Abdi İbrahim has also R&D Centers and production facilities in Kazakhstan and Algeria. Abdi İbrahim has taken an important step by signing United Nations Global Principles Agreement in 2010 and given the opportunity to share high standards which it has acquired in the fields of human rights, as well as environmental and social responsibility. Besides, Abdi İbrahim has focused its activities on sustainability studies on level A of Global Reporting Initiative (GRI) and published its third Sustainability Report

Abiogen Pharma is privately owned Italian pharmaceutical company, it was established in 1997 after the acquisition of Istituto Gentili by MSD. After 20 years Abiogen is ranked number 1 by IMS in the field of Vitamin d3 globally: due it’s success story in Italy, becoming the reference company in Italy for bone metabolism related pathologies . The key area of interest are Musculoskeletal diseases, pain management and dermatology. Abiogen is Aiming to expand it’s business globally through licensees and distributors as well as in creating synergies with partners for our CMO. Our main products for the export are Vitamin D3 (Colcalciferol), Paracetamol a full line, Paracetamol+ Codeine and clodronic acid , besides we have an interesting pipeline of innovative products in musculoskeletal diseases. We are actively scouting for partners around the world. Our state of the art facility is a attractive spot for partners who want to cooperate with us for the production of their products, we have three different lines solid oral forms (tablets capsules…), semi solids (cream, gel, ointments…) and liquids (injectables, drops, ampolues….) We are looking for partners in the countries where we are not yet present and that are willing to establish a long term cooperation . We are willing to explore the possibilities in our core areas of interest for products with a value added , we have a strong sales force in Italy and we have a network of partners around the world growing every day. So we can evaluate project for Italy as well as for a region or even globally

Aché is a 100% Brazilian-owned corporation that has been in activity for 53 years and is one of the three biggest pharmaceutical companies in Brazil. It has one of the largest demand and sales generation forces in the Brazilian market, which gives it extensive reach for publicizing its products, disseminating scientific knowledge to health professionals, and providing end consumers with access to a complete portfolio of quality products.
With 4,700 employees and always attentive to the issue of diversity and its attributes, 52% of its employees are women. More than 2,500 are dedicated to maintaining relationships with health professionals and points of sale, by way of in person and virtual visits.
The Company has a broad and diversified portfolio, consisting of 358 brands, 871 SKUs and 145 therapeutic classes, in the prescription, generic, over-the-counter (OTC), dermocosmetics, dermatological drugs, nutraceuticals, probiotics and biotechnology segments that are available in multiple channels (trade and institutional, public and private). In 2018 it was present in 72,027 points of sale and 2,067 private institutions.
Our products are also distributed throughout Latin America and other continents, totalizing 26 countries covered by licensing agreements.
Its industrial plants are located in the municipalities of São Paulo – SP; Guarulhos – SP; Londrina – PR (Nortis); and Anápolis – GO. In addition, it has a 25% stake in Bionovis (a joint-venture with three other national pharmaceutical companies), located in Valinhos – SP, dedicated to the research and development of biotechnological drugs.
A new industrial plant is under construction, located in Cabo de Santo Agostinho, Pernambuco. The plant will be in full operation in 2021.

Acino, a Swiss pharmaceutical company headquartered in Zurich, develops, manufactures, and internationally markets well-proven and innovative pharmaceuticals in novel drug delivery forms. Under the brand ‘Acino Switzerland’, Acino sells high-quality medicines in emerging markets with a strategic focus on the Middle East, Africa, Ukraine/CIS including Russia, and Latin America. Acino is a leader in advanced drug delivery technologies specializing in modified release oral forms and oral dispersible forms, for which it also holds patents. As a partner of pharmaceutical companies worldwide, Acino supplies finished in-house developed products and/or provides customized one-stop solutions from product development and registration to contract manufacturing, packaging, and logistics. .

Adamed is a pharmaceutical and biotechnology company with over 30 years of experience, founded on the basis of Polish scientific advances and a patent portfolio. A consistently implemented development strategy based on two pillars – innovation and international expansion – has made the pharmaceutical and biotechnology company Adamed a renowned global brand. We operate branches in Spain, Russia, the Czech Republic, Vietnam, Italy, Kazakhstan, Uzbekistan, Slovakia and Ukraine.

Adare Pharmaceuticals is a global specialty CDMO providing product development through commercial manufacturing expertise focused on oral dosage forms for the Pharmaceutical, Animal Health and OTC markets. Adare’s propriety technology platforms specialize in ODT, taste masking and customized drug release. With over 30 years of proven legacy, Adare has successfully developed and manufactured more than 40 products sold by partners in more than 100 countries globally.

AdSalutem Healthy Healing

Facilitating the development of effective Partnerships, Licensing In&Out, Strategic Alliances and M&A among European, Latin American and Asian pharmaceutical companies (very specially South Korea and Japan). Building and optimizing portfolio Advising in International Growth, Coordination of Strategic Projects, Portfolio Strategy, Corporate and Business Development,

Advanz Pharma is an international pharmaceutical company focused on serving the needs of patients around the world with enhanced access to high quality, niche established medicines. With operational headquarters in London (UK), an operations centre of excellence in Mumbai and commercial affiliates in North America, Europe, and Australia/NZ, we have a rich heritage of supplying and developing niche established medicines with a first-class distribution network in over 90 countries and a diversified portfolio of over 200 medicines spanning therapy areas across Endocrinology, Ophthalmology, Urology, AntiInfectives, Pain Management, Central Nervous System disorders, Oncology, Haematology, Cardiology and Intensive Care medicines. Going forward, our goal is to become the leading platform for niche established medicines, with advanced commercial capabilities throughout Western Europe through a combination of pipeline development and acquisition focusing on niche and differentiated generics, complex specialty and value-added medicines.

Alexxiapharma S.A. is an enterprise in Ecuador, with the main office in Quito. The company operates in the Drugs and Druggists’ Sundries Merchant Wholesalers sector. It was first established on July 12, 2011.

AET – Alfred E. Tiefenbacher was founded 1963 in Hamburg by the company’s namesake as the world’s first exclusive API agency, AET has a history of excellence in service and collaboration. Today AET is a fully fledged pharmaceutical company with a portfolio of over 100 products developed in its’ own laboratories and with partners, which are licensed out to market leaders globally. Clients benefit from true expertise in every stage of the generic drug lifecycle, including drug development, auditing and quality, regulatory procedure management, IP support, international launch and supply chain management. AET marketing partners also enjoy accomplished service and advice for every aspect of dossier and finished product supply, directly contributing to their successful marketing. The coordinated avoidance or removal of IP and regulatory barriers also ensures that AET clients are often first to launch. As a result AET has a reputation for market leadership in service, quality and value.

Alibaba Europe, E-commerce, Health category ALIBABA GROUP’S MISSION IS TO MAKE IT EASY TO DO BUSINESS ANYWHERE. We provide the fundamental technology infrastructure and marketing reach to help merchants, brands and other businesses that provide products, services, and digital content to leverage the power of the Internet to engage with their users and customers. Our businesses are comprised of core commerce, cloud computing, digital media and entertainment, innovation initiatives, and others. Through investee affiliates, we also participate in the logistics and local services sectors.

The origins of Alturix can be traced back to 1998 and the acquisition of three branded products from Novartis by HK Pharma. These products have been reliably supplied to the NHS and other international markets ever since, using a high-quality manufacturing partner based in Switzerland. Today, the company portfolio includes four products which help to improve patients’ health, and are supplied to customers at sensible prices. This is in keeping with the company’s stated aim of developing a reputation for reliably delivering high quality products which are priced appropriately. Our market access capability for the UK is exceptional with proven recent successes. We are in the process of launching multiple products in the coming two years and continue to look for new products to compliment our portfolio in the UK whilst also out-licensing or supplying to export markets.

Alvion is a science oriented pharmaceutical company developing and producing generic medicines in Europe. Collaborating with state of the art R&D centers, Alvion is a private and independent company focusing in R&D, IP, Quality, Regulatory, Customer service and Supply Management, developing a best in class pharmaceutical company offering a wide portfolio and services across EU, MENA, Canada, Australia, South Africa and LATAM.

Alfa Intes Industria Terapeutica Splendore S.r.l. # lfa Intes, a family business with more than six decades of experience in the pharmaceutical industry, is an italian leading ophthalmological group. The entire group is integrally engeged on the entire pharmaceutical value-chain, from manufacturing, to research and development, until marketing of a wide range of products strictly indicated for the eye-care.

Founded in Cambridge (UK), Altacor Pharma was established in 2006 as a speciality ophthalmology company. With an excellent reputation in the UK, it has achieved strong growth with a focus on ocular surface disease and surgical products. (mixture of own products and distributor/in-licensing). Acquired by privately owned company in 2014, it is now part of large pharmaceutical group. Altacor is expanding globally with a network of distributors. Altacor future growth: Looking for new product distribution opportunities (in-license); Growing portfolio within by developing our own products (out-license); International expansion through elected partners and distributors; Looking for investors for phase II product in development

Alvogen / Alvotech is a global, privately owned pharmaceutical company focused on developing, manufacturing and selling generic, brand, over-the-counter brands (OTC) and biosimilar products for patients around the world. We are passionate about making people’s lives better by making high quality medicines more accessible around the world. The company has commercial operations in 35 countries with 2,800 employees and operates four manufacturing and development hubs in the U.S., Romania, Korea and Taiwan. North America is Alvogen’s single largest market and other key markets include: South Korea, Russia, Taiwan, Romania, Hungary, Ukraine, Japan and China.

Amring Pharmaceuticals is a privately-held generic pharmaceutical company active in global markets geared to supplying unique and specialized products. The company is part of the global Amring Pharmaceuticals business and is partnered with wellestablished global biopharmaceutical companies. Amring is uniquely positioned to leverage its partners’ expertise in bringing biotechnology derived medicines, as well as patient-friendly drug delivery systems, sterile manufacturing and other state-of-theart technologies to the marketplace.

AMW GmbH is an innovative and steady growing pharmaceutical company situated nearby Munich in Germany founded in 2008. Although still a small to medium-sized enterprise, we already developed several products and act globally by providing licenses to partners throughout the world. Our partnering resp. licensing focus is the development, manufacture and distribution of medicinal products for indications such as oncology, neurology, endocrinology, ophthalmology and pain treatment. What drives us at AMW is the fact that despite significant progress in the treatment of severe diseases with highly active drugs, there are still several unmet needs in various therapeutic areas. Thus we strive for the development of an outstanding product platform to achieve the maximum benefit for the patient by significantly improving the patient’s adherence to the prescribed course of treatment. The intention of our undertaking is to provide prolonged therapeutic effects with the benefit of having less side effects due to a lower dosing regimen compared to immediate release formulations and ideally achieving uniform reliable and pain reduced application compared to alternative drug delivery forms. Therefore, our products are predestinated for the longterm treatment of chronic diseases. One example from our portfolio is a biodegradable implant, which is applied subcutaneously via an applicator with an automatic needle-retraction mechanism. Regarding the active ingredient, the implants can contain highly potent drugs such as nucleic acids, peptides or proteins (e.g. monoclonal antibodies) as well as small molecules. Our latest product is a fertility control ring. The durable ring contains less API and does not have to be stored in a refrigerator. The development of new drug delivery systems is in our „DNA“ and we continuously look for partners to create new products based on our product platform.

Anklam Extrakt® is specialised in the research, development and production of high-quality plant extracts. Our plant extracts made from leaves, flowers, roots, berries, and other parts of plants are produced solely in accordance with the requirements of the GMP and HACCP quality standards. Highest quality from the best raw material is our commitment. Anklam Extrakt® is further specialised in thedevelopment of Maqui berry extract – an innovative, branded ingredient concept supported by scientifc research for the nutrition and health industries.

Aristo Pharma Group is active within the following business fields: Marketing of generic pharmaceuticals and speciality brands in Germany, Spain, Portugal, Austria, the Netherlands, Italy, United Kingdom, Nordics, Poland, Czech, Eastern Europe and Russia with specific strengths in Urology, Gynecology, Pain, Pediatrics, Cardio and CNS. Marketing of OTC brands (pharmaceuticals, medical devices) in Germany, Spain, Austria, Portugal, Italy, Poland, Ukraine and Russia. We promote our products with a specialized sales force and by tender business.

Athena focuses on innovative and value-added Dossiers for Licensing out as well as fee-for-service development for specialty Pharma, multinational, and other established companies. Structure : 320 persons in 2 plants located in France and India, developing and manufacturing Oral Solid drug delivery systems and products (Sustained Release, Enteric Coated, Taste Masked, ODT, and fixed-dose combinations in both Rx and OTC segments

Founded in 1986 and headquartered in Hyderabad, India, Aurobindo Pharma is involved in developing, manufacturing and marketing oral and injectable generic formulations and APIs. It is the leading Indian generics company in Europe with presence in 11 countries with European sales of over €600m. Through the acquisition of the Western European operations of Actavis in 2014, Aurobindo acquired both extensive additional product lines, including over 1,250 dossier license rights and over 350 INNs, and ready-made distribution and hospital sales networks. Acquired Generis in April 2017, catapulting Aurobindo to the #1 position by value and volume in the Portuguese generic market. With the acquisition of Apotex in Europe in 2019, in Poland and the Czech Republic, Aurobindo will become one of top 15 generics companies in each country. In the Netherlands, the acquisition will lead to Aurobindo becoming a leading OTC company by volume, in Spain it will strengthen the company’s position in the generics market, and in Belgium the acquisition will provide Aurobindo with an entry into the retail generics space, where it will become a top 5 player.

Aurora Europe, headquartered in Berlin, Germany, is a subsidiary of Aurora Cannabis Inc., a global leader in the cannabis industry serving both medical and consumer markets and dedicated to helping people improve their lives. Aurora Europe supplies high-quality medical cannabis products to patients throughout Europe. In 2015, Aurora entered the German market and today operates one of the largest authorised importers and distributors of medical cannabis in Europe. Aurora’s internal network of EU GMP facilities continues to bring high-quality, premium medical cannabis to patients worldwide. For more information please visit

AV Medical is family owned company specializing in in-licensing, registering and commercialization of Rx pharmaceutical products in Czech Republic (central Europe). Company was founded in 2004 and started with pharmaceuticals in 2011. In 2019 started development of our own niche generic. Niche are always to CZ market, yet always there are molecules difficult to find for EU. Company maintain constant growth since inception each year with at least 2 digit percentage growth. We are looking for Rx molecules for CZ market to in-license. Also we would like to offer our developed molecules for out-licensing.

Aveom Pharma focuses on innovative hospital specialities. Business development services focused on hospital medicines to fuel commercial growth of its clients. AVEOM identifies new products and creates partnership opportunities, proposes to manage distribution channels and to research markets. AVEOM CONSULTING: business development services to create new commercial partnerships: identifiy key sources of supply and efficient distributors, improve launch management to optimize results, provide search assistance for C(D)MO, Reg Affairs & Market Access. AVEOM DEVELOPMENT : through licenses and acquisitions, develops intellectual property (IP) to boost market value of Marketing Authorisations and Pharmaceutical Dossiers.

Axion company is an Algerian-French Company providing Commercial execution and Hospital Distribution in Algeria and Medical Affairs in different countries such France, Algeria, Morocco and Tunisia. It is a full integrated company capable to execute customer’s strategy with a high performance in the following areas: Medical Affairs Regulatory and market access Marketing Services Commercial execution Hospital distribution Tender management We have strong track records in Algeria and France.

Axon Pharma is a private owned multinational pharmaceutical company with regional presence in Latin America. Its headquarters are located in Santiago, Chile, with subsidiaries in Colombia, Peru and Venezuela. Its core business is to develop long term partnerships with best in class innovative Pharma companies and drive their products in the region.Our executive and management team has a wealth of regional experience within the pharmaceutical industry. Today, Axon Pharma is one of the fastest growing companies with proven track record in different segments, expanding its portfolio into numerous therapeutic areas: Rare Diseases; Auto-immune diseases; Neurology / Psychiatry; Cardio-metabolic; Gastroenterology; Ophthalmology

Be Pharma d.o.o. is operating in the field of licensing in and licensing out and supply of medicines, wholesale of medicines, APIs (Active Pharmaceutical Ingredients), OTC products, medical devices and food supplements. What we offer? Marketing & Regulatory Affairs Be Pharma performs a comprehensive marketing support and business development, sales and regulatory affairs services for international partners. Integrated Pharmaceutical Services Be Pharma has a portfolio of mainstream medicinal finished products for different therapeutical areas. Together with partnering companies, Be Pharma also offers support in local packaging requirements of medicines (secondary packaging). Access to Viable API Sources The choice among several high-quality API sources with a wide variety of APIs.

Berlin Chemie AG is an innovative, internationally operating drug manufacturer with a rich tradition, located in the heart of Europe. Since 1992, BERLIN-CHEMIE has belonged to the globally operating MENARINI Group, which has been the leader on the Italian pharmaceutical market for decades. The company, which was founded in Naples in 1886 and is headquartered in Florence, has over generations been developed into a globally operating, family-run pharmaceutical company. Within the MENARINI Group, BERLIN-CHEMIE is responsible for the pharmaceutical business in Germany, Eastern Europe and the GUS region. In addition, Berlin is one of the Group’s central research sites. BERLIN-CHEMIE supplies medicines to more than 30 countries and has subsidiaries in more than 26 of them. BERLIN-CHEMIE is one of the leading drug manufacturers in Eastern Europe and the GUS region. Thanks to its historical presence in the region, BERLIN-CHEMIE boasts many years of local marketing expertise, a sophisticated distribution network and a modern production site in Kaluga, Russia.

Bernita Pharma was founded in 2008 and established itself as one of the most important pharmaceutical companies within a very short time. The company is run by management as an owner-managed medium-sized enterprise. Our product range is focused on well-known original products alongside a wide selection of the most important substances in the generics market. In addition, we offer a comprehensive range of herbal medicines, some of which have been proven for decades, as well as modern medical devices and other aids

BIOCAD is Russia’s leading innovative biotechnology company; it combines a world-class research and development center, ultra-modern pharmaceutical and biotechnological manufacturing facilities, as well as preclinical and clinical research infrastructure compliant with international standards. BIOCAD is one of the worlds few full-cycle drug development and manufacturing companies, from new molecule discovery and genetic engineering to large-scale commercial production and marketing support. BIOCADs medicines are dedicated to treat complex health conditions such as cancer, HIV and Hepatitis C infections, multiple sclerosis and other disorders.

Bioceros is one of Europe’s premier providers of GMP-ready protein producing cell lines that operates from within the PolPharma Group. Bioceros has developed a proprietary animal-component free, suspension CHO platform (named CHOBC®) that is used for stable Cell Line Development. All the Cell Line Development work that we perform is Quality Controlled. We have generated cell lines producing proteins ranging from blood proteins and monoclonal antibodies to fusion proteins and enzymes. For monoclonal antibodies, our services start based on customers wishes, either with cDNA sequences to be expressed or by generation of antibodies in rodents, followed by cloning of the sequences from selected hybridomas. Further services include immunoassays, with a particular emphasis on cell based assays, as well as down-stream process development and full analytical analysis (i.e. glycan structures, charge variants and many other relevant quality attributes). Additionally, our CHOBC® platform has enabled us to generate high-producing biosimilar expressing cell lines that have been extensively analyzed to optimize the process conditions and thus yield highly similar antibodies when compared to the originators. These cell lines are available for out-licensing or co-development in various stages of development.

Biocon Biologics is a subsidiary of Biocon Ltd, an innovation led global biopharmaceuticals company. Biocon Biologics is engaged in developing high quality, affordable biosimilars that can expand access to a cutting-edge class of therapies to patients globally. It is uniquely positioned as a fully integrated ‘pure play’ biosimilars organization in the world and aspires to transform patient lives through innovative and inclusive healthcare solutions. The Company has a large portfolio of biosimilars under global clinical development with three of these commercialized in at least one of the developed markets of EU, U.S. and Japan. Biocon Biologics has a product pipeline of 28 molecules, including 11 with Mylan, several with Sandoz and is developing many independently. Biocon Biologics believes that strong partnerships offer enormous opportunities to co-create the future of healthcare, building a patient ecosystem beyond the product, which can transform millions of lives.

BIOFABRI With over 75 years of experience and a highly qualified team of professionals to back up our expertise, BIOFABRI is focused on Human health, with strong technical, development and manufacturing capabilities and a proven track record. We focus our activities in three strategic business lines: The development and production of vaccines and biological products, the pharmaceutical division, being specialised in contract manufacturing and distribution of pharmaceutical products and the most recent, the probiotic line, focused in the development and manufacture of probiotics with highest pharmaceutical standards. Thanks to its line of probiotics, Biofabri is your preferential partner in licencing, developing and/or manufacturing probiotics in pharmaceutical formats. Our new line of probiotics focuses on galenic development and manufacturing of probiotics under the highest pharmaceutical standards. Our new line encompasses all the culture, experience and knowledge of our parent company, CZ Veterinaria, and of the rest of the group’s biotech companies to offer new and proven clinical probiotics.

Bioiberica is a global Life Science company committed to improving people, animal and plant health and well-being. Our core business is the identification, extraction and development of animal-derived biomolecules, which are transformed into high quality products for the pharmaceutical, nutraceutical, veterinary, feed and agricultural industries. Currently our porfolio is composed of APIs and ingredients such as Heparin, Thyroid, Chondroitin, Glucosamine, Sodium Hyaluronate, Undenatured Collagen and others. At Bioiberica we wish to continue growing and innovating and are seeking strategic collaborations with other companies or institutions in order to develop new businesses and products of animal origin.

Biomm is a biopharmaceutical company with over 20 year experience in biotechnology. The company is based in Nova Lima, Southeastern Brazil. We are a publicly traded biotech in Brazil (BIOM3) with a strong governance, compliance and backed by a capital structure that mixes private equity investment with national development funds. We have strong technological, regulatory and operational teams and a USD 90 M plant investment (F&F) in Minas Gerais State, Brazil. Biomm has an experienced team with special focus on biotechnological products. We have a dedicated sales force in Oncology, currently with trastuzumab biosimilar from a partnership with Celltrion. Other products in late stage negotiation or in pre-submission (bevacizumab from Biothera). We have another sales force in Diabetes with a line of insulin and analogues and other partnerships in place for biotech products (enoxaparin, teriparatide). Our main focus is in-licensing biotech products.

Bionovis is brazilian biopharma company devoted to develop, manufacture and market biologics. It was founded in 2012 as a JV composed of 4 of largest brazilian pharma companies: Aché, EMS, Hypera Pharma and União Química. Current partnerships with Janssen, Merck, Samsung Bioepis, Sandoz and Fresenius Kabi involve full tech transfer which is allowing Bionovis to locally manufacture several biologics (originators and biosimilars). Bionovis is pursuing different models of partnering, including pure licensing, co-development, tech transfer and/or manufacturing, with a focus on biologics.s.

Bio-Thera Solutions is a clinical-stage pharmaceutical company focused on biologic therapeutics. Bio-Thera is developing a pipeline on innovative enhanced monoclonal antibodies and antibody-drug conjugates for the treatment of a broad range of cancers and other diseases as well as a pipeline of biosimilars in the autoimmune and oncology therapeutic areas. The company is headquartered in Guangzhou, China.

BIOXTRACT is a Belgian based B to B Developer and Manufacturer of Innovative Food Supplements and Ingredients for Private Label Sale. BIOXTRACT’s Customers are Pharmaceutical and Food Supplement Industries Worldwide. BIOXTRACT’s expertise lies in the Development, Production and Marketing of Active Ingredients from Natural Origin, Innovative or Improved, with High Added Value. These Active Ingredients are presented in the form of Formulated Extracts that can be used as Ingredients for the Manufacturing of Food Supplements but also as ready-to-use Finished dosage forms for Private Label (softgels, capsules or tablets, in bulk or in blister and complete packaging under the brand of the customers). BIOXTRACT is FSSC 22000 and GMP certified according to NSF/ANSI Standard 173, Section 8 dedicated to Dietary Supplements for its Laboratory and Logistic/Manufacture premises.

bitop AG, a German company, is focused on the manufacturing and utilization of natural protective molecules, the so-called Extremolytes. For more than 20 years, bitop has explored and validated Ectoin®, a naturally cell protecting molecule with excellent membrane-stabilizing and inflammation-reducing properties for human use. Build on this experience, a portfolio of unique and natural OTC medical devices and cosmetics has been developed. bitop’s greatest value lies in the scientifically proven efficacy of its products and the natural and preservative-free formulations. Ectoin® already proved its efficacy and marketability successfully in various health & wellbeing products which treat and alleviate symptoms of diverse skin diseases (especially atopic dermatitis), cough&cold, allergies, ophthalmology and female intimate care. These products are marketed under brands of experienced pharmaceutical partners in more than 50 countries worldwide by now. bitop offers its Ectoin®-containing products on a B2B licensing basis to pharmaceutical companies worldwide..

Blau Farmacêutica is a Brazilian Pharmaceutical Company with more than 30 years in the market, with R$ 1,3 billion of revenue, 1,300 employees, among the leading pharmaceutical companies in Latin America, with a diversified portfolio, specialized in high complex and hospital finished dosage forms, on oncology, nephrology, hematology, infectious diseases, among others. Established in the city of Cotia/São Paulo, Blau has 5 production sites in Brazil, specialized in the production of Synthetic and Biotechnological, meeting the good manufacturing practices and quality control required by the most demanding health authorities, including Anvisa, Invima, among others.The company currently has subsidiaries in 05 countries of Latin America, including Argentina, Chile, Colombia, Peru and Uruguay. Our growth strategy relies on the full acceptance of our products in new markets, resulting in a growing demand, not only in the countries of Latin America, but also in many others around the world.

Bluepharma Group is today one of the most entrepreneurial and innovative in the pharmaceutical sector, having already achieved a remarkable prestige not only in Portugal, but also in the most demanding international markets. Throughout its 17 years, Bluepharma has transformed an industrial unit that employs 58 people, in an economic group of 18 companies and employs more than 500 employees. It has opened offices in 7 countries (Spain, Angola, Mozambique, Colombia, Chile, Brazil and USA) and exported, in 2017, 85% of its production to more than 40 countries. Bluepharma’s activity goes through the entire value chain of the drug, from R&D to the market, imposing itself for the excellence of its production unit, the quality and training of its employees and the experience and dynamism of its management team.

BMG Pharma is a B2B company developing and partnering innovative new healthcare products in the areas of oral care, dermatology including aesthetics, anaemia, osteoarthritis & cancer supportive care. The company has created a strong portfolio of intellectual property which it has developed into a portfolio of products that have been partnered with companies around the world. The company recently acquired Sigea, an Italian company with expertise in the development of innovative biomaterials, currently focused on modified sodium hyaluronate for appilcation in a number of therapeutic areas including dermatology and oral care.

Bosnalijek was established in 1951 and has since become the largest industrial manufacturer of medicines in Bosnia and Herzegovina. The company is continuously committed to its customers. Each year it strives to expand its product range with new products adapted to customer needs.

 The focus of the product range structure is on medicines of mass therapeutic application. The product range includes medicines for peroral, parenteral and topical administration with effect on the digestive system and metabolism, cardiovascular system, systemic infections, skin, musculoskeletal, nervous and respiratory system, and systemic hormonal medicines, with the exception of sex hormones. In addition to medicines, our wide product range also includes dietary supplements and disinfectants for broad consumption.

Founded by Shri I.A. Modi, Cadila Pharmaceuticals Ltd. is one of the largest privately held pharmaceutical companies in India, headquartered at Ahmedabad, in the State of Gujarat. Over the last six decades, the company has been developing and manufacturing pharmaceutical products in India and selling and distributing these in over hundred other countries around the world. Focused strongly on Innovation and Research, the company is present in more than forty-five therapeutic areas spread across twelve specialities, including cardiovascular, gastrointestinal, analgesics, haematinics, anti-infectives and antibiotics, respiratory agents, antidiabetics and immunologicals. At Cadila Pharmaceuticals, Research and Development is at the core of all its initiatives, be it Biotechnology, APIs, Formulations, Plant Tissue Culture or Phytochemistry. More than 300 scientists in its various Research and Development setups reinforce the competitiveness of research in the therapeutic areas which have high unmet medical needs. Cadila Pharmaceuticals Excellence in manufacturing facilities is central to Cadila Pharmaceuticals. The company’s formulations manufacturing plant at Dholka near Ahmedabad, Gujarat is spread over hundred acres of land. This state-of-the- art facility is not only impressive in size, but is also USFDA approved. The second formulations manufacturing facility is located at Samba in Jammu and Kashmir. The facility meets most of the stringent quality standards across the globe to produce tablets, capsules, soft and hard gelatin capsules, liquids and orals. Two Active Pharmaceutical Ingredient (API) manufacturing units at Ankleshwar, Gujarat manufacture a wide range of APIs and intermediates including many USFDA-certified products. The company has strong foothold in the African continent through its formulation manufacturing facility at Addis Ababa in Ethiopia.

Cantabria Labs is a market leader in the development and commercialization of both proprietary and in-licensed technologies and products in the market. Our extensive cooperation with other companies to develop our business includes long term licensing agreements of products and technologies to be marketed through our group of companies. Our strong position in the Spain, Italy, France, Mexico, Portugal and Morocco market comes from our knowledge, the reputation we have gotten through our R&D in cooperation with important international centers such as Harvard Medical School and our close relationship with professionals.  CL have also an international significant presence in the dermatological arena through its international net of distributors in Latin America, the US, Asia, Africa and Middle East and is strategically developing pediatrics and ENT in the countries where we have subsidiaries (Spain, Italy, France, Mexico, Portugal and Morocco). Due to our entrepeneurial spirit, we have also initiated our way in new areas such as gynaecology and trauma. Also part of this group is Nutrición Médica, providing specialized products to cover nutritional needs with added value products.   Partnering objectives: Looking for Licensing-In deals to build strong partnerships based on new products, delivery systems or cutting-edge technologies.  Several business models could fit in our collaboration agreement. Exploring also options for Licensing-Out our own products.

Capricorn Life Sciences offers pharmaceutical products with valuable USP’s (FSMP’s (Food for Special Medical Purposes), food supplements, medical devices and pharmaceutical OTC’s), all with clinical backup for marketing and distribution and/or inlicensing. Our product portfolio covers a broad range of therapeutic indications including but not limited to Women’s Health, Urology, Pediatrics, ENT, CNS, Cardiovascular Health, Neurology/Pain, Gastroenterology, Immunology and Nephrology and includes unique galenic presentations such as vapor patches, stickpacks, controlled release tablets, effervescent tablets, nasal sprays, oral sprays and throat sprays. Efficacy and safety of our products have been proven in clinical trials and/or are supported by approved EFSA claims. The products can be marketed under our ready brands but we are open to discuss supply under private label as well. Complete EU regulatory dossiers and full regulatory support are provided.

Carnot Laboratories is a 100% Mexican company focused on high technology systems in the manufacturing of their products. The company considers the launch of innovative products and continuous product renewal the cornerstone of its growth in order to meet the current requirements of the population. Carnot’s manufacturing facilities have been certified by COFEPRIS, INVIMA, ANVISA and ANMAT and is now present all over Central and South America, with affiliates in Argentina, Peru, Colombia and Uruguay. Carnot ® Laboratories adds value through its business philosophy, offering manufacturing in areas such as hormonal injectables, oral solids, oral liquids, semisolids, conditioning and inhaled biological products that meet national and international quality standards. Carnot products are based on years of experience and technological innovation.

Centax Pharma is an innovative internationally active independent company, that has specialized on the research, development, production and marketing of health products. Centax Pharma GmbH was established in 2011. We maintain close ties with the town of Stuttgart in Baden Wüttenberg, where our company is located, and our production facilities are also in Germany. Numerous innovative products secure the future of the company and offer excellent working conditions as well as promising future prospects to more than worldwide 60 highly qualified employees at the headquarters in Stuttgart and in the distribution countries. Centax Pharma develops and sells high-quality and innovative products based on the orthomolecular nutritional medicine for the international market.

Chanelle Pharma is Ireland’s largest indigenous generic pharmaceutical manufacturer of both medical and veterinary products. Serving customers in 96 countries worldwide, Chanelle Pharma is a partner of choice in the development and manufacturing of pharmaceutical products to the world’s leading human generic and animal health multinationals and distributors. We are passionate about understanding and addressing the challenges facing our medical and veterinary customers and bringing them innovative and effective products and solutions. Building on over 35 years of research and development, with over 4,500 licenses registered worldwide, Chanelle Pharma is headquartered on an 18 acre campus in Loughrea, Co Galway, with three manufacturing facilities, four research and development laboratories and a fifth R&D laboratory in Jordan. The company employs 550 people in Ireland, UK, Jordan and India. In 2018, the company announced an €85 million investment, the single largest investment by any Irish owned company, to double manufacturing capacity, launch 96 new products and grow its workforce to 850 people over a period of 5 years. As part of the investment, Chanelle opened a purpose built €10 million manufacturing facility in 2018 to facilitate the company’s expansion plans in to the US market. The facility received FDA approval in September 2019. Chanelle Pharma won 2018 Pharma Company of the Year and Industry Company of Year, the first indigenous Irish company to win the award. At Chanelle Pharma, our employees drive our success. The company is on an ambitious growth trajectory and expanding its workforce across a number of disciplines in Science, Engineering, Quality, Finance, Sales and Marketing. You will have the opportunity to collaborate in our diverse and inclusive environment, the ability to learn and grow in your career, and an opportunity to make a direct impact on our business and customers.

Chiesi Brazil. Chiesi is an Italian Pharmaceutical company with global operations in 27+ countries across EU, the US and Emerging Markets and has a well defined strategic focus on 3 areas: Respiratory, Neonatology, Special Care & Rare Disease.Chiesi Brazil is the first affiliate outside Italy, 9th largest operation, one of the 3 industrial plants in Chiesi Group and 2nd Largest operation in Emerging Markets. Chiesi Brazil is one of the leaders cia. In respiratory area and Neonatology. We are looking for opportunities & partnerships by licensing in Brazil as our local non-organic growth strategy.

Chimimportexport Plurimex SRL is a private family company operating on the pharmaceutical market in Romania for 28 years. We operate activities of procurement, warehousing and distribution of medicines, dietary supplements and medical devices. Other activities include: Registration of medicines, dietary supplements and medical devices, on field marketing and promotion for marketed products (with own field force), with their continuous support on the market, activities for obtaining price approval and reimbursement for medicines, medical support and supervision, clinical trials, pharmacovigilance activities, consultancy activities. We possess our storage spaces and authorized transport vehicles in compliance with the rules of good distribution practice. Since its establishment until now, the company has steadily increased its product portfolio, sales volume and expertise field. We are constantly working to increase the performance of our staff. Maintaining high quality standards in line with current market requirements is a constant concern of our company.

China Medical System Holdings Limited (“CMS”, together with its subsidiaries, the “Group”) is a well-established, innovation-driven specialty pharma with a focus on sales & marketing in China. The Group was established in 1995 and was listed on Main Board Market of the Stock Exchange of Hong Kong Limited (stock code: 867) on 28 September 2010. We enrich our pipeline of pharmaceutical products and medical devices by in-house R&D, license-in and M&A. We also conduct product-orientated equity investment, via  CMS Medical Venture (a corporate venture fund of CMS), and A&B fund (a family office’s investment vehicle).

Clinigen (Clinigen Group) is a global pharmaceutical and services company with a unique combination of businesses focused on providing access to medicines to improve the quality of people’s lives around the world. We are the global leading experts, trusted by both pharmaceutical and biotech companies and healthcare professionals, in providing access to medicines throughout the lifecycle of a medicine; clinical trials, unlicensed and commercial supply. Operating in a complex regulatory environment, Clinigen is the only company to globally manage access to medicine across all three routes. We understand the complex challenges facing Pharmaceutical and Biotech companies and are uniquely placed to provide the solutions to help

Cole Pharmaceuticals is a commercial-stage specialty pharmaceutical company engaged in the development and commercialisation of innovative treatments to fight against vitamin D deficiency. Vitamin D deficiency is a global public health issue. Cole Pharmaceuticals is adressing the problem by providing patients with user-friendly formulations and delivery technologies aiming at giving compliant and pleasurable experience. Cole Pharmaceuticals operates with a sales and marketing organization in Belgium and Luxembourg. The company is commited to be a trusted partner for development with other pharmaceutical companies around the world. Cole Pharmaceuticals does out-licensing of its products and in-licensing of carefully selected products covering food supplments/OTC, devices and drugs.

Cooper Pharma is a global pharmaceutical manufacturing company, which is renowned internationally for its quality standards and efficacy of products. We are committed to making the world a healthier place through the development, production, and marketing of excellent pharmaceutical products. We are one of the oldest and top pharmaceutical companies in India. We are a global pharmaceutical manufacturing company, exporting to more than 25 countries across the globe. We are involved in the manufacturing of pharmaceuticals, pharmaceutical distribution, marketing, and exports. We are a part of the prestigious Cooper group, which was established in the year 1959. Our manufacturing unit is located in the lush green environs of Dehradun, Uttarakhand in North India. Our corporate office is located in the capital city of Delhi, India. We have huge capacities to manufacture tablets, capsules, syrups, ointments, sterile powder injectables and liquid injectables. Cooper Pharma has been conferred with awards such as the cGMP, WHO-GMP & ISO 9001:2008 certifications that meet all quality parameters and norms. The plant conforms to international standards like USFDA, UKMHRA, and TGA-Australia. Efforts are still in progress for getting them accreditation.

CoraPharm is a licensing and distribution company with its own affiliate offices in Slovenia, Bosnia and Herzegovina, North Macedonia, Montenegro, Kosovo, and Albania. Our focus is on state tenders. Interested in injectables, oncology, dialysis, orphan and unregistered drugs and medical devices.

Coripharma is a new European pharmaceutical company, based on solid heritage. Coripharma’s experienced team offers contract manufacturing and development services to pharmaceutical companies all over the world, companies that demand the highest quality, from a reliable European supplier

Cosmos Pharmaceuticals Limited The importance of medicines can only be realised when they are readily available when required. With that in mind Cosmos started in 1978 with the sole aim of manufacturing quality generic medicines at an affordable price for Kenyans. Many of whom required essential drugs defined by the World Health Organization as “those that satisfy the priority healthcare needs of the population”​. At Cosmos we believe quality is of paramount importance and there is only 1 quality when it comes to medicines. Adhering to strict Good Manufacturing Practices and being technologically advanced to our competitors we were able to achieve this by the turn of the century through both public and private partnerships. One of only a few companies in the region with over two hundred registered products, the next aim was to make non-communicable diseases and diseases where medication had to be taken regularly a priority. Through very active Research and Development we are able to practically adapt medication for the ever growing requirements of the private market, spearheading a movement to increase the quality of life, convenience and compliance of the people. Cosmos is now a 3rd generation family business of technocrats with a passion for the industry that has grown to have a presence in 10 Sub Saharan African countries and employ 400+ people. Our latest aim is to gain international standard recognition through WHO prequalification for the majority of our products.

Course5 Intelligence enables pharma and biotech organizations with actionable insights through primary and secondary research thereby improving efficiency and effectiveness of strategic decision making. We have expertise in identifying in-licensing and out-licensing opportunities using both primary and secondary intelligence techniques. In a recent project we evaluated over 300 assets in 40 indications using our proprietary prioritization framework and narrowed it down to five highly probable targets for our client. This project helped our client to cut down the total deal time by several months and had a direct impact on their bottom line.

Polish CRO responsible for monitoring services in clinical trials. Experience in early phases (including FIH) as well as phase II and III studies.

CSA Healthcare GmbH is a professional management consultancy company headquartered in Frankfurt with offices in US and Thailand. We focus on Corporate Strategy, New Market Entry Strategy, Portfolio Management, and M&A in the pharma and biologicals space. We help our clients in fine tuning their business strategy, finding new geographical and product opportunities to ensure mid and long term profitable business growth. In M&A we specialize in commercial due diligence, evaluation of business plans & advising our clients on underlying risks and potential upsides. We also support our clients in interim management and business integration. Our clients include pharma & healthcare companies, private equity firms & other investors, and global management consultancy companies.

“A WORLD, FREE FROM THE LIMITATIONS OF CHRONIC CONDITIONS” CuraLife is a nutraceutical company of new generation with a unique focus on the #1 healthcare challenge of our times: chronic conditions. Born from the personal needs of its Founder/CEO to find a real solution to his T2 diabetic father, CuraLife has reported unprecedented growth since its launch in 2016 and it is quickly gaining a leading role in the world of natural solutions for chronic conditions management. CuraLife’s first product is CuraLin: nutraceutical solution for T2 Diabetes. Diabetes is currently #1 healthcare challenge for many Governments around the world and conventional drugs offer a limited level of efficacy and safety. CuraLin reported sales in 50+ countries and a recent survey run by Pr. Itamar Raz on CuraLin’s clients highlighted “Satisfaction” and “Referral” rate. CuraLin was nominated “Best natural solution to lower blood glucose levels” in the UK in 2019 and an extensive international double-blind placebo-controlled clinical trial started in early 2020. CuraLife’s partners around the world are extremely satisfied for the social impact and the high financial returns: “The relationship with the CuraLife Team is the dream of every partner: it provides confidence, cutting-hedge strategies, problem solving and precious best-practices that pushes our business way beyond our forecasts” Tal Zuri, CuraLife’s partner in China CuraLife is about to launch in 4 new markets and to open 3 new offices: Italy, UK and France.

Curida is a Norwegian Contract Development and Manufacturing Organization (CDMO) with a manufacturing site in Elverum, and offices in Oslo Cancer Cluster. Our core competency is the development and manufacture of liquids and semi-liquids formulations, based on sterile unit-dose Blow-Fill-Seal (BFS) technology, Spray and Bottled products. Currently we manufacture ophthalmics (unidose/multidose), nasal formulations, wound care products and injectables for large multinational companies as well as for smaller, more niched companies. We are EU-GMP certified for approved and investigational medicinal products and ISO-13485 certified for medical devices. Through the years we have worked with commodities as well as with more complex projects including controlled substances, delivering on time to satisfied customers. We handle small-scale volumes as well as more complex quantities of SKU’. Curida was founded in 2015, following an employee and management buy-out of a Takeda site. So while it is a young and agile company, it also builds on over 40 years of experience in the development and manufacture of pharmaceuticals, medical devices and nutraceuticals. Our most valuable asset is our people. A highly skilled and experienced organization, and we are all dedicated to create value for our customers by being a flexible, enthusiastic, reliable and brave business partner.

Dafra Pharma is a privately owned pharmaceutical group of companies that aims to improve the public health in Sub-Sahara Africa. Dafra Pharma markets medicines and health solutions complying with the highest European quality standards. The continuous scientific training of our sales force contributes to the recognition of our company as a reliable partner in the extensive local network.

Deerland Probiotics & Enzymes® offer expert know-how in probiotics and enzymes globally. The company specializes in developing science-backed solutions that benefit microbiome and systemic health, based on pre- and probiotic and enzyme technologies. Clinical validation, stability testing and unprecedented quality are the cornerstones of a unique line of dietary supplements offered as white label to customers globally. Deerland Probiotics & Enzymes serves its customers from several locations worldwide and manufacture all products in quality certified facilities in North America and Denmark.

DEMO S.A. Pharmaceutical Industry is an industrial and commercial organization established in 1965 and active in the production and sales of pharmaceutical products. During the past years, DEMO S.A. has achieved a significant growth in all its business segments. This growth has enabled us to achieve results that are a testament to the quality and dedication of our employees. No1 Producer of pharmaceutical products in Greece; No1 in Sales Growth among Greek pharmaceutical companies within the Top 100 Greek industries; Official Supplier of the United Nations; Official Supplier of UNICEF

DESITIN Arzneimittel GmbH is a medium-sized, independent, family owned specialty pharmaceutical company with focus on CNS. Desitin is headquartered in Hamburg (Germany) and operates in Europe with subsidiaries in UK, SE, DK, NO, CH, CZ, SK and RO and a Pan- EU-Partner-Network. Own developments of improved known active ingredients as well as in-licensing of innovations are the corner stones of Desitin´s success in CNS – with proven track record.

Deva Holding A.Ş Founded in 1958 in İstanbul, DEVA Holding is one of our country’s well established local pharmaceuticals producers with 2000 employees, 3 production plants (EU-GMP & US FDA approved) and an R&D center. DEVA has concentrated its efforts on increasing human health and quality of life since its foundation. Our target is to ensure vertical integration in strategic products as a pioneer in the development of generic drugs, to become a world-class player in developing active agents and new polymorphs, to create difference by developing value-added products, to continue developing products for regulated markets (EMA and FDA), to invest in the future by adapting new technologies to our company, to develop products with a high added value by ensuring university industry cooperation and to ensure the protection of our intellectual property rights through patent registration.

Devintec Pharma is a private and independent company based in Lugano. 

Our business is based on advanced Research & Development that leads to discovering, developing, and successively licensing innovative healthcare solutions such as substance-based medical devices, topical medical devices, cosmeceuticals, cosmetics and food supplements.

DKSH is a public company headquartered in Switzerland. DKSH Healthcare is the largest Commercialization company in Asia, working with all global pharma, device and OTC companies. The Healthcare division reached over 6 bill USD sales employing nearly 10,000 people. We have affiliates across 15 countries in Asia with more than 4,000 Sales and Marketing professionals. DKSH also owns and distributes Women’s Healthcare products to more than 40 markets via Medinova AG, based in Zurich. DKSH owns a proprietary dermocosmetic range in scar care management (face scar, acne scar…)  to license out and we have in it, an innovative and unique silicone gel medical device for c-section scar  designed for OBGY, HIRUSCAR SILICONE PRO. This device has a PhIV study in this indication (study just terminated in Thailand). DKSH sells the skin care full range for more than 40m USD in APAC, being leader in most of countries..

More than 125 years of tradition in pharmaceutical production. A leading role in the areas of women’s health and hemorrhoidal complaints in Germany. International activities in the growing markets of Asia and Eastern Europe: that is DR. KADE! Our mission is “to make qualitiy of life”: We aim to bring high quality health solutions successfully to people throughout the world who assume responsibility for their own health. DR. KADE is a family owned, independent and constantly growing pharma company in Berlin. Market leading brands such as KadeFungin, OeKolp, Posterisan, Faktu and others have created high patient awareness and top physician ratings in Gynecology & Proctology in Germany. With innovative products DR. KADE is also a competent partner for doctors and patients in pain therapy – e.g. for treating back pain. Through joint ventures and sales cooperations we are not only active in the German market, but also in other European and non-European countries, for example in Poland (through our Joint Venture Kadefarm) and Japan (Maruho). We are driving our domestic & international business by a) expanding the geographical reach for our portfolio and b) looking for OTC and Rx products + late-stage projects.

Dr. Pfleger Arzneimittel GmbH is an independent, medium-sized pharmaceutical company focused on innovation. Established in 1945 and located in Bamberg, we offer products and services – Made in Germany.In co-operation with domestic and international pharmaceutical companies, Dr. Pfleger operates as both a licensor and a licensee for OTC and Rx products. The company develops and markets pharmaceutical products, medical devices and other healthcare products, with a primary focus on urological, gynaecological, and dermatological indications. Dr. Pfleger also offers full-service contract development and manufacturing in its state-of-the art production facilities exclusively in Germany: production and packaging of tablets, film-coated tablets, hard capsules, suppositories and semi-solid forms.

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses – Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastro-intestinal, cardiovascular, diabetology, oncology, pain management and dermatology.

We are one of the leading generic pharmaceutical companies in Central Eastern Europe, and our activities incorporate all areas of the pharmaceutical value chain. Egis is a member of the Servier Group, an international pharmaceutical company governed by a non-profit foundation with its headquarters in France. In the 2019/2020 financial year, Egis Group generated net sales of EUR 542 million. Besides Hungary, we sell our products under Egis’ brand names in 17 countries through our network of subsidiaries and representative offices.
Our focus lies on treating diseases of the cardiovascular and central nervous systems; however, we also provide modern treatment solutions in the fields of oncology and women’s health. In 2013, we launched our first biosimilar monoclonal antibody product. This was also the first biosimilar monoclonal antibody (mAb) in the European Union. Since then we launched three additional biosimilar drugs.

EirGen Pharma Established in 2005, EirGen Pharma has state of the art R&D facilities, an exceptional high containment environment, a thriving Commercial Centre and rigorous Project Management systems. EirGen’s global operations and outputs are led by our highly experienced, dynamic management team, supported by our talented and dedicated workforce. EirGen Pharma is a world leading developer and commercial supplier of specialty medicines to the global market. EirGen has a reputation for excellence and quality in the fast moving, competitive pharmaceutical industry. We provide versatile, price effective and efficient solutions to partners seeking to collaborate in pharma healthcare. EirGen has a blemish free inspection record and is a trusted supplier of best quality, safe and reliable life saving high containment medicines. EirGen operates in the global market with specialty medicines available in over 50 countries worldwide. Our significant roster of international approvals includes the FDA (USA), EMEA (Europe), and the PMDA (Japan). EirGen was named Pharma Company of the Year at the Irish Pharma Industry Awards 2017. A subsidiary of OPKO Health, EirGen Pharma is strategically situated in a beautiful coastal location in Ireland, Europe.

ELC GROUP is a fully-fledged global regulatory partner, working with major pharmaceutical stakeholders for over a decade. From the development stage through to the implementation of clinical trials, completion of product registration, and successful marketing of the product, ELC GROUP aligns itself as a strategic partner to help pharmaceutical companies achieve their healthcare goals.

Emcure Pharmaceuticals Ltd Emcure is a multinational pharmaceutical company leader in India market and operating in more than 80 countries across the world . Manufactures, and commercializes generics and some innovative products in HIV area, Onco – Hemato , chirals , biossimilars and hospital sector (injectables mainly) . In Latin America we have products registered in more than 23 countries and direct operation in Brazil, Mexico and Peru.

Emona Biopharma is a GMP company from Slovenia, that specialises in the developing and out-licensing of generic pharmaceuticals for the European markets. Our partners are pharmaceutical enterprises that license, register, and sell our products under their own marketing authorizations. Emona Biopharma offers pharmaceuticals to European marketing partners: solid forms OTCs and Rx, as well as a number of hospital injectables.

Enorama Pharma AB is a Swedish pharmaceutical company. We focus on development and manufacturing of consumer friendly medicated chewing gums containing well proven generic substances. We have a unique manufacturing model and a devoted staff with extensive experience from the medicated gum business.

We are an Italian CDMO highly specialized in solid oral delivery forms for pharmaceuticals and food supplements, focusing on: EFFERVESCENT; ORALLY DISINTEGRATING; SOLUBLE; SUBLINGUAL. Especially in the Generics and OTC/Consumer Health industries. We offer to pharmaceutical companies opportunities of: contract development/ contract manufacturing/ out-licensing + supply with their brand, worldwide. Our plant is located in Trento, in the North of Italy, and it is duly authorized to produce pharmaceuticals, even investigational medicinal products, and food supplements. We are GMP authorized by AIFA (Italy) and by Russian Health Authorities. We are also registered to produce food supplements by FDA, TGA as well as by Emirates.

Esserre Pharma is an Italian certified innovative SME, established in 2013, operating in the nutraceutical market and active in the cardiometabolic, mental well-being, immuno-nutrition, and anti-inflammation areas.
The company is committed to study and provide premium Mediterranean-based finished products ensuring their safety and efficacy. Our formulations are supported by clinical trials and protected by intellectual property and are currently marketed successfully in more than 20 countries worldwide. Our target is bringing to the market nutraceutical products fully developed and produced in Italy, following a strong scientific rationale, creating all around the world partnerships based on Mediterranean excellence.

Ethypharm We are a European-based speciality pharmaceutical company with global reach and a committed player in the treatment of pain, addiction and critical care. We also develop and market speciality drugs and generics that provide added value to healthcare providers and deliver high quality medicines for patients.

Eurofarma is the first Brazilian multinational pharmaceutical company, founded in 1972, present in Latin America. It operates in all major pharmaceutical segments, occupying the 2nd position in the most prescribed laboratories ranking by the Brazilian medical community and is among the Top 4 generic drug laboratories in the country. Holder of a broad range of products, it also holds licenses and strategic partnerships for the promotion and marketing of third party’s products. The company’s sales added up to around US$ 1 billion in 2014, reaching a 20% growth over the previous year. Licenses accounted for 10% of the total, approximately. Eurofarma has the largest medical sales force in Brazil (about 2,000 representatives) and is considered one of the best companies to work for, according to key publications. The company keeps its own operations in 15 countries, has over 10 manufacturing plants strategically located and an ambitious internationalization plan with growing investment in the R&D area.

FAES Farma is an international pharmaceutical group from Spain. Listed in the Madrid stock market. Own innovative patented portfolio and developments. Strong Momentum with 2018 sales of 324 € and double digit growth (+18%). Key business pillars: Prescription drugs, Consumer healthcare, Animal nutrition

Faran SA is a Greek pharmaceutical company that aims to offer renowned high quality therapeutic products, with high therapeutic value, modern pharmaceutical technology and documented Safety. To achieve this goal our horizons expanded daily with selected international partnerships and the trust of medical community by providing therapeutic solutions in a wide range of diseases in the area of Oncology, Haematology, Nephrology, Orthopaedics, Rheumatology, Endocrinology, International Medicine and Gynecology. At the same time drawing on our decades of experience, since 1950, in the pharmaceutical area, at local and international level, have introduced quality criteria depending on the structure and the function and are designed to actively contribute to the development of a modern healthcare environment cooperating closely with healthcare professionals, authorities, patients and community.

FarmaSyn S.A. FarmaSyn S.A. operates in the domestic market, employs a 44-person salesforce (medical representatives and sales people) and cover just over 9000 doctors and 4000 pharmacies. Our employees visit Pathologists, Orthopedists, GPs, Cardiologists, Otolaryngologists, Pediatricians, Neurologists and Psychiatrists. We also own our own distribution network, facilities and warehouse.  (GDP,GMP) Apart from our own PL products, we also proudly hold three strong collaborations with Sandoz GmbH, Engelhard Arzneimittel GmbH and Cheplapharm Arzneimittel for a broad line of pharmaceuticals (Rx, OTC), as well as medical devices.

We at Ferrer aim to establish long-term relationships with biopharmaceutical and biotechnology companies that are active in the therapeutic areas we consider strategic. In our licensing-out strategy we look for companies with presence in the therapeutic areas of interest with presence in Europe, North America, South America, Asia, Middle-East and Russia&CIS. In the scope of this exhibition, we are not interested in discussing contract manufacturing, API&packaging sourcing or licensing-in opportunities.

Fine Foods & Pharmaceuticals N.T.M. S.p.A. With revenues of € 146 Millions expected in 2019, approximately 1200 SKUs and more than 600 employees, Fine Foods & Pharmaceuticals NTM’s is a Contract Development and Manufacturing Organization with no proprietary brand, producing Pharmaceuticals, Dietary Supplements and Medical Devices in solid oral forms. The two manufacturing sites are located in Zingonia, (Dietary Supplements and Medical Devices) and Brembate (Pharmaceuticals), all a few miles from Bergamo, Northern Italy.

FranceMed Pharma with its solid base in the British Market since 1981 and NHS reimbursable listings, owns Market Leading patented, innovative topical micro-fine sprays classified as OTC/ therapeutic Medical devices Class IIa (faster registration). The sprays have unique attributes & all are groundbreaking, disruptive with No Competition & No Me-Toos. The company is active in R&D /Synthesis /Screening /Pre-Clinical /Clinical Phase I, II & III Studies / Regulatory Registration/ Manufacturing/ Marketing /Sales/Distribution and Global Out-licensing in 40+ countries and growing. The patented OTC products treat acute & chronic conditions in Dermatology, Paediatrics, Gynaecology, Ophthalmology, Pain Management, Neurology, E&T, Oncology, Diabetes, Vascular Diseases, Rheumatology, First Aid, Allergy, Men & Woman’s Health and Veterinary Medicine. FranceMed Pharma is a privately owned company with a strong Balance Sheet.

Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion, and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients.Fresenius Kabi’s product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the devices for administering these products. In the field of biosimilars, Fresenius Kabi focuses on autoimmune diseases and oncology. Within transfusion technology, Fresenius Kabi offers products used in the collection and processing of blood and cell components, as well as in transfusion medicine and cell therapies. With its corporate philosophy of “caring for life”, the company is committed to putting essential medicines and technologies in the hands of people who help patients and finding the best answers to the challenges they face. Fresenius Kabi employs over 40,000 people worldwide. In 2019 the company reported sales of more than €6.9 billion. Fresenius Kabi AG is a wholly-owned subsidiary of the Fresenius SE & Co. KGaA health care group.

FRIKE GROUP is an independent and diversified contract manufacturer for pharmaceutical products. We are able to produce and fill semi-solid, fluid forms and suppositories. FRIKE GROUP is the Holding of 5 individual production companies on 5 locations in Switzerland. We are Swissmedic and FDA certified

Pohl-Boskamp is one of Germany’s leading mid-sized pharmaceutical companies. With several generations of expertise coupled with our pronounced innovative drive, we help patients all over the world with products marketed under our brands. Our family company based in northern Germany has made a name for itself all over the world with fast-acting formulations with highly tolerable effects. We meet the most stringent international quality standards, of regulatory agencies from all over the world, including the U.S. Food and Drug Administration (FDA). Pohl-Boskamp is a global player: About 45 percent of our products are produced for export and sold in 50 different countries. Our independent family company, now in its fourth generation, develops innovative products while looking ahead to the future with confidence. We are proud of our independence and the ability to think and act on a long-term basis.

Gador is a company with 80 years of experience in the pharmaceutical industry with an important presence in South America and more than 50 countries in 4 continents. Our purpose is provide a better quality of life and access to health through high quality medicines. Gador is offering the opportunity to develop in-licensing projects in South America. Currently our company has the confidence of more than 20 high standard partners worlwide, like Gilead, Astellas, Novartis, MSD, Alvogen, Nordic, and others, allowing us to offer to our markets a portfolio of innovative products and high added value medicines.

GALPHARMA Laboratories is a major Tunisian Pharma company specialized in non sterile generic medicines lined up with the highest standards of pharmaceutical quality requirements. Manufactures oral Non-penicillin and Non-cephalosporin (NPNCs) Finished Dosage Forms (FDFs) across multiple therapeutic areas and multiple forms. Will manufacture oral FDFs for Penicillins / Cephalosporins by 2021.Moreover we are engaged in the development of the latest pharmaceutical generics, provided with updated CTD and eCTD dossiers.

Gebro Pharma is a privately-own European Pharma Group focused in development, manufacturing and commercialisation of innovative pharmaceutical products. Gebro Pharma is interested in expanding its portfolio through partnering with pharma companies, biotechs and other players. We are also open to asset acquisitions. We have an extensive track record of alliances with big pharma companies (Novartis, Recordati, Astrazeneca, GSK), international players (medac, Luye, IBSA, Ferrer, SMB, …) and biotechs (Can-Fite). Headquarters are located in Fieberbrunn (Austria) with subsidiaries in Spain, Switzerland and Hungary and a network of partners around Europe and beyond. The therapeutic focus of the Group is pain with a strong franchise in Rheumatology. Alongside, we have also built a portfolio around urology, respiratory, GI, derma and CV. Strong commercial structures, local regulatory know-how and investment commitment are key aspects for commercial success and long-term partnerships, making Gebro a company of choice for multi-territory or regional deals in Austria, Switzerland and Spain.

Geiserpharma is a pharmaceutical company specialized in research & development activities for value-added products, by implementing advanced technologies and new drug delivery systems within the main pharmaceutical areas: Niche Generics Rx Products, OTC Products and Medical Devices.

Genepharm has been committed to the development, manufacturing, marketing and distribution of generic pharmaceuticals since 1967. Privately held, the company has three state-of-the-art production facilities designed in accordance with EU cGMP requirements. With respect to our dossier development (CTD and eCTD-format), Genepharm’s dedicated scientific team aims at delivering several new dossiers each year.

Genericon is an Austrian pharmaceutical company specialized in quality generics since its foundation in 1986. Genericon is one of the most respected pharmaceutical companies on the Austrian market. The wide range of products covers the fields of cardiovascular, metabolism, neurology, urology, gastroenterology, pain and infection. The product portfolio is constantly evaluated and expanded. +pharma is member of the Austrian based Genericon Pharma group. +pharma arzneimittel gmbh was established 2006 in Austria with the aim to attract new customer segments by focusing on direct marketing. +pharma Polska Sp z o.o and +pharma Česká republika s.r.o are successfully operating on the local markets since 2008 and strives to grow along with the increased demand for affordable, high-quality drugs.

GeneriNobel is a privately owned pharmaceutical company, based in Germany. We represent and outlicense the generic dossiers (Rx and OTC developments) of Turkish multinational Manufacturer NOBEL Ilaç (own R&D and manufacturing of APIs and finished products) to all European markets. Key therapeutic areas are cardiovascular diseases, central nervous system and metabolism.

Gensenta Pharma is one of the leading and oldest pharmaceutical companies in Turkey founded in 1912 and acquired by Amgen in 2012. Gensenta Pharma offers new and comprehensive solutions to more patients on a wider geography with main product groups of: Hospital Injections, Oncology, Antibiotics, Corticosteroids for it’s global customers and distributors

Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. We operate primarily under a business to business (B2B) model and have an excellent track record in the development, manufacturing and marketing of complex injectables. This presence across the value chain has helped us witness exponential growth.

GP Pharm is a privately owned pharmaceutical company based in Barcelona (Spain). GP Pharm is specialized in the development, manufacture and marketing of innovative and generic injectable products. GP Pharm products are manufactured in our state of the art manufacturing facilities in Barcelona (Spain).Our products are injectables based on the use of peptides as API’s and/or in our in-home developed drug delivery systems using technological platforms based on Microspheres and Liposomes. Today, our products are sold in more than 40 countries worldwide.The therapeutic areas of interest of the company are urology, oncology, women‚ health and hospital products.The activities of the company are focused in: out-licensing of our portfolio, in-licensing for the Spanish market and CDMO activities.

Granata Bio is a US-based biopharma company focused on Reproductive Health. With the vision of creating a robust fertility therapeutic portfolio, we bring expertise in commercialization as well as late-stage clinical and regulatory development in North America.We are seeking in-licensing or co-development opportunities to bring established molecules to the US and Canadian markets.

Grunenthal Global Operations team maintains five specialized plants on two continents. The plants in Germany, Switzerland, Italy, Ecuador and Chile operate as full-service CMOs vertically integrated from active substance to finished products with a strong service portfolio including controlled drugs handling, regulatory services, production process design, export into 100 countries worldwide and special technologies such as hormones, hot melt extrusion or biopharma packaging.

H.A.C. Pharma is a French independent specialty pharmaceutical company.H.A.C. Pharma wishes to be recognized as an hospital partner by providing therapeutics solutions suited with patients’ needs and healthcare professionals’ expectations. H.A.C. Pharma is focused on this goal by maintaining market availability of essential and experienced medicines portfolio.

hameln pharma plus gmbh is a family-owned company and part of the hameln group, is specialised in the global sales and distribution of hospital injectables that are primarily used in intensive care units and in the field of anaesthesiology. Among other products, our portfolio comprises various controlled drugs. Our products are sold into more than 40 countries, either through our own sales force or through local distribution partners. We are looking for opportunities to in-license new injectable products and value added medicines or to discuss opportunities to discuss the distribution of our portfolio in new markets. In addition to the above, our sister-company in Slovakia offers e.g. development, laboratory or regulatory services.

Helm AG is a Hamburg based privately owned company and represented by own subsidaries in more than 30 countries worldwide. In cooperation with highly acclaimed international partners, Helm offers developments of generic pharmaceuticals.

HENNIG Arzneimittel is a mid-sized family-owned German pharmaceutical company based near Frankfurt with 120 years of grown experience. Its success is based upon four main pillars: HENNIG Arzneimittel offers proprietary drugs to the German market in the indication vertigo and disturbances of equilibrium where it is market leader. Besides this HENNIG Arzneimittel manufactures and offers a broad range of generics – among these all generically available antivertigo products. Further core areas regard cardiovascular, metabolism, pain, neurologic and psychiatric products. A rapidly growing range of over-the-counter drugs, devices and food supplements is complementing HENNIG’s product portfolio, strengthening its consumer orientation. The fourth pillar is contract manufacturing and contract development services, both for pharmaceuticals and food supplements, with a special focus upon complex solid dosage forms for modified release. Technologies include tableting, coating, dry and wet granulation, extrusion, pelletising, dry-coated tablets and capsule filling, as well as blistering and secondary packaging. The equipment allows easy scale-up from lab scale to industrial scale. HENNIG Arzneimittel offers customer-specific services, ranging from feasibility studies up to full service.

At Hikma we put better health within reach, every day in more than 50 countries around the world. For more than 40 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people’s lives. We’re committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,600 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world.

Hypera Pharma is Brazil’s largest pharmaceutical company in net sales. It’s present in all relevant segments of the retail pharmaceutical sector in Brazil, with leadership in several product categories. The company offers high-quality products, and keeps investing in innovation to grow in a sustainable way.

IBI Istituto Biochimico Italiano G. Lorenzini S.p.A. is an Italian pharmaceutical company with global reach and 99 years of experience. It has a consolidated leadership in sterile penicillin market and capability of aseptic filling for injectable drug products, aimed to offer new solutions to doctors and health to patients. IBI is characterized by and integrated and flexible structure and it offers a platform from production to commercialization for our customer’s needs, with affiliates in IT, GE, UK. We are committed to think creatively to innovation and investing for cutting-edge equipment and new partnerships for drug development in Biotechnologies and Nano-particles and we offer to our commercial partners a platform for project co-sharing.

IBSS BIOMED S.A. – an expert in vaccines and probiotics – is a Polish biotechnology company operating continuously since 1945. We make exceptional products, which are the effects of the synergy of our experience and the knowledge of reputable research institutes and modern technologies. For over 65 years, we have enjoyed the trust of patients, physicians and business partners. The basis of IBSS BIOMED S.A.’s activity is the production of: probiotics, vaccines (also those included in the Preventive Immunization Schedule), dietary supplements, allergens, as well as diagnostic preparations, media and indicators. We are known for innovative solutions and inventive ideas, which allow us to maintain the highest quality of the manufactured products and, as a result, satisfy customers’ expectations. The company constantly improves its products so that they meet quality and market requirements, and are compliant with the highest standards of modern pharmaceutics by: introducing new manufacturing technologies, research methods, modernising the equipment of our laboratories. The areas of the company’s activity: Production (own, contract manufacturing and research) R&D of the company’s own products (clinical trials, registration) Sales and marketing Export/import

Idifarma provides CDMO services for niche and highly potent drugs With an experienced staff of 130+ people and over 100 international clients, Idifarma provides a full range of services covering most of the lifecycle of any pharmaceutical product from first pre-formulation trials to commercial manufacturing: drug formulation, development and validation of analytical methods, stability studies, regulatory affairs, GMP contract manufacturing and packaging for clinical or commercial use, with extremely low MOQs. Our state-of-the-art facility features a purpose-built high containment plant for GMP manufacturing of oral solid dosage forms, for both highly potent and non-potent drugs. We have invested in Spray Drying capabilities, being able to develop and manufacture drug intermediates improving the bioavailability of low soluble APIs.

ILKO Pharmaceuticals has over 650 employees and holds a strong product portfolio in acute and chronic therapeutic areas for Rx and Consumer Healthcare products. Activities in biopharmaceuticals are in progress by development of biobetter and biosimilars. EU-GMP approved manufacturing facility has 120million packs/year capacity. Business opportunities: Import&Export, In&out licensing, Contract manufacturing.

InfectoPharm Arzneimittel und Consilium GmbH is a leading pharmaceutical company in the German paediatric field and received in the last consecutive 17 years the award “goldene Tablette” from the German paediatrician society for its innovative drugs and services. InfectoPharm, founded in 1988, is a familiy owned business engaged in the development and commercialisation of prescription and nonprescription medicines for paediatric therapeutic areas such as infectiology, dermatology, pneumology and allergology as well as hospital antibiotics. InfectoPharm has been working for more than 30 years in partnership with paediatricians and patients and developed specialities which fit paediatricians therapeutic needs and chlidren compliance demand. In the hospital care field we support hospital physicians with special active substances, which, even under difficult circumstances, are effective or help to avoid the development of resistance. We are particularly focusing our attention on infections associated with the disease of cystic fibrosis. We are conducting clinical trials to prove our product efficacy and have a strong regulatory expertise.

Inpha is an Italian company, specialised in the development of innovative Nutraceuticals, characterised by a high scientific rationale. The efficacy of our formulations is supported by clinical trials and protected by intellectual property. The products are developed by our own ”sister company” Inpha Research, applying to supplements a new scientific approach, based on the rigorous study of biomechanical and physiological mechanisms, supported by sophisticated pharmaceutical technologies in order to increase the absorption and bioavailability of every active ingredient.

INSUD PHARMA operates across the entire pharmaceutical value chain, delivering specialized expertise and experience in scientific research, development, manufacturing, sales and marketing of a wide range of value-adding active pharmaceutical ingredients (APIs), finished dosage forms (FDFs) and branded pharmaceuticals, for human and animal health. While the main offices are located in Madrid, Lugano, Buenos Aires, INSUD PHARMA is acting worldwide, creating a broad and balanced manufacturing and commercial network across Europe, America, Asia and Africa, to address global opportunities and customers needs in all major pharmaceutical markets. INSUD PHARMA’s activity is organized in three synergistic business areas: Industrial (Chemo), Branded (Exeltis) and Biotech (mAbxience), with over 6,000 professionals in more than 40 countries, 15 state-of-the-art facilities, 10 specialized R&D centers, 12 commercial offices and more than 35 pharmaceutical affiliates, serving 1,150 customers in 96 countries around the world. INSUD PHARMA believes in innovation and sustainable development. Our commitment is to improve people`s health and quality of life, providing access to quality medicines at affordable prices, and to continuously expand our efforts and R&D investment to develop new and better therapies.

Intas Pharmaceuticals Ltd. is a leading multinational pharmaceutical company that specializes in formulation development, manufacturing and marketing generic, added value and biosimilar products. We are present in more than 85 countries worldwide and growing at a 20% rate and with more than 10,000 products registered worldwide. We are market leader for generics in the UK and also placed among top 7 companies in our domestic market in India. Continuously investing in I+D and increasing production capacity (with several GMP approved sites…

Italfarmaco is a privately-held specialty pharmaceutical company, engaged in the development, manufacturing, marketing and sales of branded prescription and non-prescription pharmaceutical products, with sales exceeding 800 M$, 1700 sales reps, and a strong commitment to R&D through the investment of roughly 10% of its turnover. Italfarmaco Group has a worlwide coverage with operations in US, Europe, Middle East, Africa, Latam and Vietnam through its own subsidiaries. Italfarmaco specializes in Women´s Health, Pediatrics, Musculoskeletal, Inmuno-Oncology, CNS and Supportive Care, while is also present in the Respiratory, Dermatology, Oral Care or Gastrointestinal fields. We are actively looking for new In licensing opportunities, in ready to market or late stage assets (Business Development) and in the preclinical up to PoC space. We are also keen to explore M&A opportunities for US and EU and out-licensing opportunities for SEA, LATAM and CEE markets.

Jamp is a Canadian company with a large portfolio of OTC and Generic products looking to expend its presence globally through strategic partnerships with local distributors

Jerusalem Pharmaceuticals Co. (“JePharm” in short) is a multinational, public-listed Company established in 1969. A producer and marketer of Generic Medicines and Veterinary products, is active over the whole of the Middle East and North Africa Region (MENA). The Company’s strong Regional presence is consolidated through an extensive Product Portfolio with over 280 SKUs and is facilitated by 5, strategically located Manufacturing Sites (Palestine-2, Jordan and Algeria-2), strong Regulatory Affairs Departments in the key Countries and two dynamic R&D sites. JePharm’s Medical Devices Division is a relatively new addition and is actively involved in associating with well-established Producers of Medical Devices in order to strengthen its portfolio in the regional Markets. The JePharm Group of Companies has been experiencing growth and profitability for 50 years now and is an equal opportunities Employer with more than 400 employees of high Educational level (average ratio of Male: Female employees at 66% : 34%).One of JePharm’ s key strategies is to seek Partners and develop new business opportunities through the establishment of strong collaborations; develop win-win practices, and pursue the business in the MENA or other Regions. Biosimilars, and related technology products targeting illnesses that are difficult to cure, and niche therapies (oncology products, hereditary diseases and genetic therapeutics, modern preventive medicines, blood derivatives, vaccines etc.) lie within the inner circle of JePharm’ interest. The JePharm Group of Companies, as a knowledgeable, flexible and highly efficient operator in the growing and complex Pharmaceutical Markets of the MENA Region, has gained sufficient momentum as to look ahead into the future positively, anticipating sustained growth and success.

Founded in 1991 in Croatia, JGL is a growing international pharmaceutical company specialized in the development and production of value-added sterile products in the segment of ophthalmology and ENT, and leader in the use of seawater for health purposes. Key strategic technologies are sterile drops, sterile sprays and bag on valve (BoV). We adhere to the following standards: EU GMP; Russian GMP; Canadian GMP; CE certificates; ISO certificates ; FDA (Mutual Recognition Agreement). JGL offers out-licensing and distribution business models for its own products: Seawater preservative free nasal sprays (mechanical pumps and BoV) Xylometazoline preservative free nasal sprays Sodium Hyaluronate preservative free eye drops

Kashiv BioSciences, LLC is a fully integrated biosciences company headquartered in Bridgewater, New Jersey with locations in Piscataway, NJ, Chicago IL, and Ahmedabad, India. Kashiv BioSciences’ broad business offering includes drug delivery platforms incorporating delayed release technology and gastric retention systems that improve the efficacy and safety of known drugs, a 505(b)(2) pipeline of development products targeting unmet clinical needs, biosimilars and prodrugs. Additionally, as part of a development collaboration Kashiv BioSciences has approved generic products and products in advanced stages of development, including several complex generic products. Kashiv BioSciences’ medications will improve the lives of patients suffering from cancer as well as neuromuscular, movement and endocrine disorders, among other debilitating conditions, both in the U.S. and globally. The combined breadth of expertise in small and large molecules, peptides, proteins and monoclonal antibodies enables Kashiv BioSciences to develop products with meaningful clinical differentiation and a compelling value proposition for patients, physicians and payers.

Khiron Life Sciences Corp. is positioned to be the dominant integrated medical cannabis company in Latin America. Khiron has core operations in Colombia and is fully licensed in the country for the cultivation, production, domestic distribution, and international export of both THC (tetrahydrocannabinol) and CBD (cannabidiol) medical cannabis. With a focused regional strategy and patient oriented approach, the company combines global scientific expertise, agricultural advantages, branded product market entrance experience and education to drive prescription and brand loyalty to address priority medical conditions such as chronic pain, epilepsy, depression and anxiety in the Latin American market of over 620 million people. Further information on the company can be accessed through the following link:

For nearly 200 years Klosterfrau Healthcare Group has been developing, manufacturing and selling pharmaceutical products. Today, our company offers an attractive portfolio of over 30 brands and nearly 200 products in Germany. Initially established in Austria and Central Europe, the Klosterfrau export sales network now also includes Central Eastern and Western Europe as well as countries in North America, Africa and Asia. Our portfolio ranges from well-known and established brands, such as Melissengeist® / Melisana®, neo-angin® and nasic®, to products for very specific indications. Klosterfrau relies above all on the healing power of nature, for this is what our company is based on. Klosterfrau continuously develops and improves its products as well as customises the product line to new trends, research results or changing social landscapes. Klosterfrau also conducts research to bring entirely new brands and products onto the market in order to make use of its potentials.

JSC PHARMASYNTEZ Leading manufacturer of socially important drugs in Russia. Our specialization is development and production of generic and innovative medicines. Product Portfolio consists of 180 generic and 2 innovative products. Our five high-technology plants produce medicines in all dosage forms: tablets, capsules, granules, infusion solutions, sterile powders, injectables. We are opened for cooperation.

Kéri Pharma Group is specialized in the sales and marketing of RX and OTC products in the Hungarian market. We offer: diosmin 1000 mg filmcoated tablet for out-licensing or distribution (food supplement and/or OTC ); in-depth knowledge of the Hungarian pharmaceutical market, professional marketing unit with strong specialized field force for companies intending to have market access in Hungary: We are interested in: out-licensing diosmin 1000mg filmcoated tablet as FS and OTC; in-licensing and/or distribution of innovative and specialty drugs, RX and OTC; niche/specialty generics; orphan generics; brand acquisitions, the takeover of existing MAs for Hungary. Main focus: – urology – vascular, gastroenterology – rheumatology.

Kern Pharma is a Spanish company, leader in the development, manufacturing and marketing of generic medicinal products, with a portfolio that includes the majority of therapeutic areas, 150 molecules and more than 450 presentations in the market.Biologics is Kern Pharma’s division focused on biosimilar medicines, born from the merger of the company with Celltrion Healthcare, one of the leading biotech manufacturers in the world with its headquarters in Seoul (South Korea). With this alliance, Kern Pharma is a market leader in Spain and Portugal with the monoclonal antibodies Infliximab, Trastuzumab and Rituximab.

Knight Therapeutics Inc. (TSX:GUD) is a publicly-traded, specialty pharmaceutical company focused on in-licensing late stage innovative prescription pharmaceuticals in Canada and Latin America We are a specialty pharmaceutical company looking to in-license the commercialization rights for innovative assets in Canada & Latin America. We have annual revenues of >US$180M, fully integrated operations in 11 countries (including Canada, Brazil, Mexico, Argentina and Colombia), and a strong portfolio of specialty medicines including for oncology, infectious diseases, and CNS. Our roster of existing partners includes large multinationals such as BMS/Celgene, Gilead, AstraZeneca, and Eisai, as well as biotech companies such as Puma and Ardelyx. We would like to explore a potential partnership to commercialize biosimilar and bionovel products as well as other incremental innovation type of products.

Kreussler Pharma is a medium-sized, independent, family owned company with its headquarter in Wiesbaden (Germany) and subsidiaries in France and Benelux. Kreussler Pharma have been developing, manufacturing and selling pharmaceutical drugs, medicinal products and cosmetics on the national and international markets since the division was founded in 1948. They focus is on two main areas: Self-medication for the mouth and throat: Dynexan Mundgel® is one of the most commonly prescribed medicinal products in Germany for painful oral mucosa, gums and lips. Phlebology and proctology: Our sclerosing agent Aethoxysklerol® is available in more than 50 different countries, offering sclerotherapy solutions for varicose vein sufferers of the legs. It can also be used in treatment against heamorrhoidss. Kreussler Pharma is the world’s leading manufacturer in this sector.

We are a Japanese based Global Specialty Company. We have a broad portfolio of products across many therapy areas. Current strategy is focused upon the following areas: Oncology, CNS, Nephrology, Immunology & Allergy. We are not interested in talking to any future partners regarding our global portfolio of brands including Crysvita, Nourianz, Porteligeo. We also have a portfolio of Established medicines, in the supportive care arena and we would like to focus our discussions on these products. See attached list of products available here: We are also looking for in-licensing / acquisition of divested assets.

Labatec is a privately owned Swiss-based pharmaceutical company with more than 50 years of experience in delivering high quality products to the European and Emerging Markets. Covering both the hospital and retail sectors, we have a portfolio of over 65 products and a growing geographic footprint.

Labomed – A healthier future

Labomed S.A. is a Greek privately owned CDMO service provider, originating from the merger of LaboServe S.A. (established in Dec.2016) and Documed Limited (established in May 2015). Focused on integrated pharmaceutical services for generics and added value medicines of oral liquid dosage forms, Labomed has already accumulated significant know-how, intellectual property rights and projects intended for commercialization in Europe and US, mainly through Out–licensing & Supply model.

Our ‘state-of-the-art’ manufacturing facilities (EU-GMP approved), headquartered in Athens, Greece, are supported by in-house QC laboratory, robust quality systems and a team of specialists and high experienced personnel. It is this combination of expertise and infrastructure that makes Labomed your preferred business partner for the development and manufacture of liquid products containing controlled substances (psychotropics and/or narcotics). 

We offer licensing rights and optimized supply agreements for differentiated, tailor-made added value generic products. Amongst other, a proprietary pain management portfolio addressing moderate to severe pain, is available as unique presentations and drug combinations. 

We integrate drug development capabilities with optimized, cost-effective manufacturing solutions, in order to streamline your pathway from the laboratory to the market. Our scientists pair decades of pharmaceutical development experience to assess, identify and implement the right solutions and help discover added value. Labomed goes beyond the expected, offering guidance backed by leading-edge technologies and expertise in product development, technical transfers and scale-up.

Having several patent applications submitted to EU & US, 8 products already approved in EU, 11 products under registration, and 4 products in Pipeline, Labomed is currently expanding in the development and manufacture of Cytotoxic/ high potent products.


Labaratorios Rubio is a company dedicated to the development, manufacture and marketing of products with a preferential focus on pharmaceuticals, medical devices and diagnostics in CNS, musculoskeletal, nephrology/urology and cardiovascular risk.

LACER is a Spanish privately-owned Pharmaceutical Company, founded in 1949 and headquartered in Barcelona (Spain).The main activities of the pharmaceutical division are promotion, marketing, commercialization and distribution of prescription products in the fields of Gynecology, Urology and Cardiovascular in Spain. Our goal in Pharma Synergy: We are actively seeking to expand our portfolio through in-licensing of prescription products in the fields of Gynecology and Urology.

Laboratoires SMB S.A. is a Belgian based pharmaceutical company with global ambitions, has used its 50-years experience, know-how and state of the art technologies to identify and develop its own Drug Delivery Systems designed for selected active ingredients to improve patients’ outcomes. S.M.B. is internationally recognized in the field of human health care in high-tech areas and has experienced a continuous growth on international markets thanks to its recognized expertise in drug delivery systems and its innovative medicines and is now present in over 50 countries worldwide. S.M.B. proposes a balanced portfolio of products mainly in Respiratory tract, Cardiovascular system, Pain management, Dermatology and OTC

Laboratórios Atral develops, produce and distributes a wide range of products, including prescription drugs (brand and generic), non-prescription drugs, veterinary products and also dietary supplements. Founded in 1947, Laboratórios Atral were pioneers in Portugal in the production of antibiotics. These continue to be one of the company’s core business segments, since we have facilities dedicated to the production of Penicillins and Cephalosporins, however, production currently covers other therapeutic areas. Laboratórios Atral also provides contract manufacturing services as the development and manufacturing of oral, semi-solid, liquid and injectables formulations. As partners we are able to customize specific activity models for the paths that our clients intend to achieve from the scientific design of the project to the delivery of the final product. Another important business area, is the Licencing-in that aims the expansion of Atral product’s portfolio in different therapeutic areas in order to strength our position in the National market. But what makes us competitive? Laboratórios Atral has an outstanding marketing and sales team, with a high level of experience and knowledge in several therapeutic areas, which promote the products among the doctors, at the hospitals and also in the pharmacies. Laboratórios Atral also has an International department that has a great national and international networking, which allows faster distribution of the products to the different parts of the globe.

Laboratórios Basi Mission is to develop, manufacture, market and distribute at a global level medicinal products and therapeutic solutions marked by the excellence of European quality, supported in innovative technologies in a flexible and competitive way. We are known as a reference in the manufacturing of semi-solid forms, liquid forms, small and large volume parenterals. Laboratórios Basi supports its activity in 4 key pillars: Flexibility, Innovation, Competitiveness and Eficiency. We are offering Licensing and Supply, Contract Manufacturing, R&D and Quality Control Services.

TargEDys is a clinical stage biotech company based in France with offices in Rouen and Longjumeau, Paris. TargEDys has raised over €10M in Series A funding to translate its unique understanding of the gut-brain axis to develop and manufacture nutritional and therapeutic solutions to control metabolic diseases. The company aims to be at the forefront of safe and effective weight management to improve the health and quality of life for over and underweight people.

Tillomed is a European Pharmaceutical company with headquarters in the UK and subsidiaries in France, Spain, Germany, Italy and Czech Republic. Tillomed specialises in the licensing and marketing of cost-effective generic pharmaceuticals and is focused on growth through product launches and EU expansion. Our ambition is to grow our commercial structure in Europe and to accelerate our expansion through sustainable partnerships. We strive to offer new medicines that meet genuine needs and deliver effective, high-quality, sustainable healthcare. Tillomed is owned by Emcure, a privately held company with a strong track record of launching high quality, innovative medicines. Emcure is one of India’s leading pharmaceutical companies with 11,000 employees in over 70 countries and sales over $800m.

Lamda Laboratories (a Clinigen company), is a one-stop-shop for Generic and Super Generic developments. We are looking for companies interested in custom development services or in-licensing our own dossiers. We provide full services in the whole development chain – from inception to registration to post approval finished product supply and regulatory support – creating added value products with distinct advantages for patients and health care providers. We offer tailor-made services: from simple once off analyses to custom developments in our GMP certified laboratory, specializing in formulation development, analytical development and QC.

With 100 years of existence, LETIPharma is a multinational biopharmaceutical company, specialized in immunology and dermatology. Striving for internationalization, LETIPharma is looking for distribution partnerships worldwide. LETIPharma offers: Effective dermatological solutions for skin problems as atopic skin, lip repair, redness skin with more than 130 supportive medical studies. A unique and specialist portfolio for the diagnosis and subcutaneous and sublingual treatment of allergic rhinitis/allergic asthma.

Libbs Farmacêutica manufactures pharmaceutical products and ingredients. The Company offers pharmaceutical products in the areas of cardiovascular, gynecology, central nervous system, dermatology, oncology, urology, respiratory, and gastroenterology.

We have registered offices in Belgrade (Serbia, Life Pharma) and in Ljubljana (Slovenia, Rhei Life) and we are dealing as a representative and distributor of worldwide pharmaceutical producers of biological and biosimilars, original and generic medicines, food supplements, and medical devices. We are present on following markets: T1 markets non-EU: Serbia, Bosnia, Montenegro, Albania, North Macedonia. T2 markets EU: Croatia, Bulgaria, Romania, Hungary, Slovenia and Poland.

Lipid Systems Sp. z o.o. is a modern pharmaceutical company, owning the unique, patented technology of active substances efficient closing in liposomal carriers, allowing their effective transport in the body. We have the ability to produce state-of-theart liposomal formulations of medicines, medical devices and food supplements in international quality standards.

Lo.Li. Pharma International is an Italian pharmaceutical company operating from 2012, specialized in food supplements and medical devices and focused on high quality and innovative solutions. It’s engaged in research, development and marketing of original formulations and each product is based on an accurate and complete scientific documentation supported by international literature. The company’s focus is Women’s Health, while the therapeutic areas covered are Gynecology, Obstetrics, Fertility (male and female), Endocrinology and Urology. We believe in supplying our partners with specific training and useful marketing tools in order to develop solid projects and fruitful and cooperation Our products are currently marketed successfully in more than 60 countries worldwide. We are constantly looking for distributors from all over the world who share our values and are willing to expand their portfolio with our finished products in order to establish win-win partnerships.

Lunan Pharma is a leading pharmaceutical company in China,who was ranked 22th in Top100 pharmaceutical companies in 2019.Its total sales amounted to 1.6 billion dollars . We had submitted 3 ANDAs for US, such as Rosuvastatin calcium tablet,Isosorbide mononitrate ER tablet, inhalation sevoflurane.And We will submit about 8 ANDAs&MA every year in the future. Drug application for Insulin Glargine and Pegfilgrastim had been accepted by NMPA.PD-1 are in Phase I,Rituximab biosimiliar are in Phase III. Lunan Pharma is devoted to becoming a large-scale, comprehensive, leading domestic level and world class pharmaceutical research and manufacturing base

Lupin is a global pharmaceutical company offering Branded and Generic Formulations, Biosimilars and Active Pharmaceutical Ingredients (APIs). Founded over 50 years ago, Lupin today is a significant player in the US, India and Japan and additionally in other counties within APAC, EMEA and LATAM. It holds a global leadership position in Anti-TB and Cephalosporin segments. Today Lupin is focused on building a meaningful pipeline in women’s health in USA, Neurology in Europe and Japan, Cardiac, Diabetes and Respiratory in India and Ophthalmic and Dermatology in LATAM. With 18 world class manufacturing facilities benchmarked to international standards, are spread across India, Japan, USA, Mexico and Brazil. Our 20,000 strong team of experts embrace the values of Lupin to create a winning culture as well as engage in leading research programs from new drug discovery to generic research that is helping us meet the unmet medical needs of our customers around the world.

mAbxience is a biotechnology company specialized in the research, development and manufacture of biosimilar monoclonal antibodies, part to the pharmaceutical Insud Pharma Group. Set up in 2009, it currently has two facilities for development and production, in Spain and Argentina. In December 2014, it launched its first biosimilar, rituximab, which is now approved and distributed in many markets globally. Its second product, bevacizumab, was launched in its first market in November 2016. mAbxience we develop the highest quality biosimilars through our state-of-the-art development and analytical platform. Our work methodology is our identity. A methodology that guides us in each of our decisions, focused on quality and efficacy: Developing biosimilars adhering to a strict “quality by design” standard.

Macter International Limited is one of the leading branded generic formulator in Pakistan with over 35 years of manufacturing and marketing experience. Macter has also been a contract manufacturer of finished dosage forms for leading MNCs such as Novartis, Pfizer, Jansenn Cilag, Merck, Reckitt Benckiser and P&G. Macter manufactures annually more than 50m packs of a wide range of forms such as tablets, capsules, dry powder suspensions, syrups, ointments / creams, ampoules, vials, metered dose and dry powder inhalers. Macter is the only company in Pakistan with a CGMP compliant facility to produce lyophilized biologic formulations. We are one of the fastest growing Pharma companies in Pakistan and consistently placing #1 in new product sales over the last three years.

Mallinckrodt Pharmaceuticals is a specialty pharmaceutical company which was founded in 1867 and has been advancing in the field of science and medicine for more than 150 years. In 2013, it embarked on a new and exciting chapter when the company became independent once again. Mallinckrodt has since undergone transformational change and has emerged as a patient-focused specialty pharmaceutical company with a diverse portfolio of innovative products and a promising pipeline. The company markets branded pharmaceutical products for immune-mediated diseases in the specialty areas of Neurology, Nephrology, Hepatology, and also a particular focus in treatment option in the Critical Care hospital setting In December 2018, Mallinckrodt announced plans to further transform the company by separating what is now the Specialty Generics from its Specialty Brands business, which is expected to create greater strategic focus for both companies, and has the potential to unlock and increase value over the long term.

We service ~90 countries worldwide – if you are looking to expand your product reach we can assist you. The leading speciality pharma company in emerging markets, our promise is to build partnerships, expand opportunities and deliver life-changing medicines Office Locations: London (UK), Florida (USA), Sao Paulo (Brazil), San Salvador (El Salvador), Bogota (Colombia), Montevideo (Uruguay), Dubai [2020] -We offer flexible market penetration models, from named patient supply to licensing deals -In-house regulatory know-how with successful submission, registration and launch in LATAM, MENA, Caribbean, and CENAM. -UK/US governance and strict adherence to current compliance measures to reassure partners, particularly when dealing with emerging markets -Extensive knowledge and expertise of regulations and close partnerships with local Health Authorities and KOLs -Global sales and marketing operations with local market knowledge and KOL network -Robust Quality Management Systems for end to end enclosed controlled distribution of medicines including controlled drugs.

Max Zeller Söhne AG is a leading phyto-pharmaceutical company in Switzerland specialized in the research, development, production and sales of clinically documented herbal drugs (both OTC and Rx). Zeller products are marketed in many parts of the world; including Europe, Asia, South America and Asia. We offer various products for out-licensing in the areas of gynceology, CNS and allergy. The key strengths of Zeller medicines are: Claims are supported by clinical studies performed using Zeller products published in peer-reviewed journals; EU/ICH standard CTD dossiers are available; Swiss-made phyto-pharmaceuticals with over 150 years of expertise and experience. · The products are leaders in their category in Switzerland and are marketed abroad in more than 25 markets.

MedAgora is a service provider for pharmaceuticals, medical devices, food supplements, and cosmetics. We support our clients in finding licensing partners, distributors, and clients in all European markets (EU and non-EU) and all other medium and large markets worldwide. OUR PRICING IS FIXED. We charge 1,000 EUR – 3,000 EUR per market (based on market size) for 1-3 products/specific set of capabilities. The price grows for each additional product/capability. 50% down payment, 50% after project finalization, once we deliver enough substantial feedback to Client’s reasonable satisfaction. OUR TIMELINES ARE FIXED. The standard deadline is set 3 months after project initiation. It is calculated based on number of markets/products/capabilties. Our business model and deliverables are COMPLETELY TRANSPARENT. We do not require any protection clause.

MEDICE is an independent, owner-managed family business founded by medical professionals and managed by medical professionals to the very today. We therefore see ourselves not only as a reliable partner and fair employer, but also as a dynamic engine of medical advancement.

Medifood is a medical nutrition company, developing, manufacturing and commercializing its innovative disease/condition-specific FSMP (Food for Special Medical Purposes) product portfolio – MediDrink. These are specially formulated, ready-to-drink medical foods that are processed and intended for the dietary management of diseases, disorders or medical conditions of individuals treated under medical supervision, to contribute to the efficacy of the medical treatment, help patients to fight the disease and recover more quickly. The products are reimbursed and are available through prescription by doctors (Rx, OTC) in many countries (also in EU), mainly from the following therapeutic areas: oncology, pulmonology, gastroenterology, nephrology, surgery. We are seeking distribution partners in selected territories to license-out our product portfolio and expand our geographical presence.

Medinfar is an independent and fully integrated Portuguese Pharmaceutical Group with R&D, Production, Marketing & Sales and Distribution. The company manufactures and markets prescription medicines, generics, OTCs/Consumer Health products and veterinary products. We offer medicines, cosmetics, food supplements and veterinary products to outlicense with our brand or private label. We manufacture our products in our GMP plant located in Portugal. The plant also offers contact manufacturing. Medinfar is nº1 Portuguese company in OTC and dermatology. Medinfar has an affiliate in Morrocco and distributors in more than 50 countries.

We are reaching you for strategic partnership with your esteem company. MEDINOMICS HEALTH CARE PVT LTD was established in 2004 by a group of partners with years of experience in pharmaceutical industry with a commitment to create better quality of life by providing high quality formulations especially, but not limited to, in Niche segment like Nutraceuticals and Pharmaceuticals. We are star export house as accredited from Government of India. We have presence in more than 30 countries around the globe. We also have shareholding in a manufacturing unit which is based in Chennai under our group company Ocean Healthcare Pvt. Ltd. Along with this we have strategic tie up with a manufacturing unit for regulated markets except for UK, Philippines and Malaysia. For us, manufacturing is a specialised work not a trading activity and we claim that we deliver only best of quality products with the state of art manufacturing.

Company focuses its Core Activities on 2 major therapeutic areas: therapeutic skincare and gynaecology/women’s health. With the key products in this segment being Gynoflor®, Fluomizin® and Nystalocal® offering physicians a comprehensive therapeutic concept that can be successfully applied for the most common vaginal infections. Besides that, Medinova also developed strong core competencies in other categories, e.g. Cough & Cold, Sleep support, Respiratory and Pain management. Medinova is not only strong in Switzerland, but also internationally with its products being marketed in more than 60 countries with a clear focus on Europe, Asia and Latin America. Medinova in Asia as part of DKSH Healthcare has access through its sister company to contract sales team numbering over 3000 sales representatives in Hospitals, Clinics and pharmacies across ASIA and ASEAN. Our group has decades of experience building brands across Asia in the healthcare segments.

Pharma-Quality Cannabis Products
MediPharm Labs, a contract and development and manufacturing company, brings a pharmaceutical perspective to the cannabis industry; working to internationally recognized pharma-quality standards, our cannabis products that are PURE, TRUSTED, and PRECISELY DOSABLE for patients and end consumers.

MediXia is a specialty healthcare and pharmaceutical company. MediXia is a subsidiary of Medica Group. Medica Group has been operating in the healthcare space since 1999, with current operational presence in >18 countries within MENA & ASIA PACIFIC serving millions of patients annually. We focus on providing therapeutics that achieve significant clinical performance, improve patient outcomes, & deliver economic value, particularly where unmet medical need exists in certain therapy areas, such as rare diseases, genetic disorders, neurology, immunology, oncology & other specialty medicines. Our ultimate goal is to be the commercial partner of choice for leading healthcare & pharmaceutical corporations across MENAT region.

MEDOCHEMIE was established in 1976 in Cyprus by Dr Andreas Pittas and is still driven by the same philosophy: “to provide every human being around the globe with quality and affordable drug treatment in a manner that supports sustainability”​. We develop, license, manufacture, market, and distribute branded generic and super-generic pharmaceutical products as well as our own patented brands. Company’s therapeutic areas: Analgesia/ Anesthesia Cardiovascular Dermatology Endocrinology Gastroenterology Immunology/Inflammation Infectious Disease Neurology Urology. The driving force behind Medochemie is our 1,370 multinational, talented, quality-focused employees, many of whom hold advanced degrees. We offer opportunities for suitably qualified applicants in a wide range of roles at our manufacturing plants, scientific laboratories or sales offices worldwide.

MedServa GmbH is a privately held networking company locaded in center of Europe in Freiburg / South Germany, between Basle and Strasburg, founded in 2001.
We support small/medium sized HEALTHCARE companies with innovative products in internationalising their business in Europe, from Lisbon to Moscow, mainly CE Medical Devices, Nutraceuticals, Dermocosmetics and OTC products.
Our aim is to reduce “go to market” time and costs for both partners in generating sales thus “Creating healthy business” in true win/win mode. We are not a consulting company, our focus is to produce sales opportunities.

Specialties: branding of healthcare products, European marketing

Providing products and services across the full industry value chain, Midas Pharma is a mid-sized pharmaceutical company that provides a wealth of expertise while connecting companies, people and knowledge. Our core competence is project management around pharmaceutical supply chains. During this Pharma Synergy Event we would like to focus on: Contract Development of Finished Drug Products Midas offers “one stop shop- solutions” with comprehensive management of all project phases. We assess the feasibility of the product candidate and manage the development, IP protection, registration as well as the supply of the finished product ready for marketing.

moksha8 is a specialty pharmaceutical company focused on the commercialization of innovative and established therapeutics in the two major Latin America markets, Brazil and Mexico. Our understanding of the regulatory complexities, our stringent quality assurance, our adherence to international standards and our integrated service offering make us the perfect partner for pharmaceutical companies looking to establish, maintain or expand their business presence in the major two Latin America Pharmaceuticals markets. Our vision is far-reaching. We aim at becoming the preferred pharmaceutical partner for high-value innovative and proven therapies across Latin America. Our commitment to making effective therapies accessible to Latin American population is at the center of our business.

MSD is a leading global biopharmaceutical company that has been inventing for life for more than a century. Bringing forward medicines and vaccines for many of the world’s most challenging diseases. Through our prescription medicines, vaccines, biologic therapies, and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. Today MSD continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world. For more information visit

The Mundipharma global network of independent associated companies seeks to identify and accelerate the development of meaningful medicines that add value for patients and healthcare providers around the globe. Founded in the US by two physicians in 1952 and still privately owned the network has a presence in over 120 countries. As a network, we have a strong track record of building successful alliances to license, develop and market medicines that improve patients’ lives, while also providing attractive options to financially constrained healthcare systems. Consistent with our entrepreneurial heritage, we like to think we see what others don’t by challenging conventional wisdom and asking different and challenging questions. We are global leaders in pain medicines, with a significant, and growing presence in our three other core therapeutic areas of respiratory, oncology and biosimilars. However, we are also open to new partnership opportunities that will enable us to realize the potential of medicines at all stages of maturity across other therapy areas.

MyBiotech is a CDMO offering end to end development, manufacturing services and innovative products with a special focus on nanoparticles and microparticles for biotech and pharma. At MyBiotech innovative technologies are part of the solution bringing your project one step closer to success. Our long years of experience in particle development and analyses is reflected into efficient development strategies for particulate systems. With our experienced team we understand the challenges in pharmaceutical development and use them for our advantage to make sure particulate systems meet your specific formulation needs.

Nanolek #NANOLEK is a modern, fast-growing Russian biopharmaceutical company, specializing in the production of import-substituting and innovative drugs. Our high-tech full-cycle production facilities fully comply with GMP and ISO standards. Our portfolio features products both developed in-house and created with international partners. NANOLEK focuses on the prevention and treatment of socially significant diseases. Today, the company is a leader in the production of pediatric vaccines in Russia. NANOLEK’s diversified medicinal product portfolio features therapeutic areas including vaccines, drugs for treatment of HIV, cancer, and other diseases. NANOLEK has a unique experience in technology transfer and commercialization as part of out partnership with global pharmaceutical leaders. We have excellent capabilities for market access to Russian and CIS markets.

Nathura Spa is an Italian Manufacturer of natural-based food supplements and medical devices, market Leader in the segments of fibres and melatonine. Having achieved a consolidated position in 25 years of successful results in the domestic market, Nathura is now proposing its products portfolio and marketing services to the international markets. OUR PRODUCT PORTFOLIO: PSYLLOGEL FIBRA: psyllium-based powder for bowel regularity; LEVIANTIS: NEW LAUNCH 2017- Osmotic laxative with 4 natural extracts (Tamarindus, Ginger, Caraway, Frangula); effective action on constipation (PATENT PENDI; CELEGYN: hyaluronic acid-based cream providing healing, anti-inflammatory and immuno-modulating activities. (II B MEDICAL DEVICE- PATENTED); ARMONIA: Melatonin-based tablets and drops for a natural approach to sleep disorders (also for paediatric use). Available in 3 formulations RETARD, FAST and ORO .(MELATONIN 99,9% PURITY); TRIXY : An innovative natural treatment to counteract NAFLD (non alcoholic fatty liver disease) Synergic action of active principles Berberine, Tocotrienols and Green Coffee (CLINICAL TRIAL)

The National Institute for Health Research is funded by the UK‚Äôs Department of Health and Social Care to provide a range of free services to support rapid study set-up and patient recruitment into all phases of clinical research studies. The NIHR:funds high quality research to improve health; trains and supports health researchers; provides world-class research facilities; works with the life sciences industry and charities (activities include research mapping and targeting, national protocol review by KOLs and a robust site identification service); involves patients and the public at every step. These free-of-charge services cover the life cycle of a clinical study.

Neolpharma Group has  more than 40 years of experience in the pharmaceutical market.  More than 300 products commercialized and under development within the main therapeutic classes of the Mexican pharmaceutical market and rest of the world. #1 company for CNS in México.

Neopharmed Gentili is an Italian pharmaceutical company specialized in the production and marketing of solutions with high therapeutic value, and an important player in the national pharmaceutical market. Neopharmed Gentili has developed through external growth, thanks to a series of partnerships with big pharma companies and acquisitions which contributed to strengthen the company’s image as a serious and dynamic enterprise, with a wide portfolio of products in several therapeutic areas: from drugs for the treatment of vascular, cardio-metabolic and respiratory diseases, to antibiotics and osteoarticular treatments, as well as over-the-counter medication and supplements. The search for innovative products to improve the health and quality of people’s life is at the heart of our business. We communicate this vision through our passion and daily commitment and over 380 employees share it.

Neosanté Health Solutions is a Portuguese healthcare company that licenses innovative, high-standard products, allowing people all over the world to improve their life quality and well being. Neosanté works in the OTC markets in several health areas, such as Pediatrics, GI, OB/GYN, ENT, CNS and Orthopedics and has all its Food Supplements and Medical Devices produced in GMP / ISO 13485 certified facilities in the European Union.

New.Fa.Dem.S.r.l. is an Italian pharmaceutical company, engaged in the developing and manufacturing of own drugs and medical devices in gastroentherological and gynecological therapeutic areas. We are looking for the distributors worldwide for our RX product and patented medical devices.

Next Wave (India) is a Pharmaceutical Company established in 2006. The company was established with the sole aim of supporting the medical fraternity by manufacturing quality medicines. The company has the facility of manufacturing finished dosage forms of Tablets, Liquids, Capsules, and External Applications. The facility has been accredited with WHO-GMP and PIC/s-GMP certification and the world-class laboratory has been awarded GLP certification. The Company boasts of cGMP compliant Formulation Development Lab as a key strength for New Product Development.

A leading provider of contract manufacturing and product development services to top Indian & MNC Pharmaceutical companies. The company along with its employees is dedicated to delivering quality products in the market, upscaling and manufacturing differentiated formulations.

Contract Manufacturing
We have been a CMO partner for different domestic and international businesses. We are a quality manufacturer for custom manufacturing of finished formulations in Private Label. At Next Wave India, we have customised packaging options for tailormade solutions.

Product Development
We have a Co-development model for better and transparent sharing of ideas and tech-transfer. We believe in an exclusive developmental model for each project maintaining accuracy and establishing reliability. We strictly follow ICH guidelines and international regulations.

In/Out Licensing
We provide Out-Licensing Services of Marketing Authorisations for formulation patents. We also In-Licensing of Products for research and developmental processes. We often work in a Co-Marketing model for International Marketing.

Normon is a Leading Spanish company in the generic market both in the hospital market and in the retail market, with over 250 generic products developed and marketed. Our new outstanding manufacturing facilities include – oral forms: tablets, film coated tablets, bilayer tablets, capsules, sachets, syrups and suspensions. – parenteral: vials (liquid, solid), ampoules, freeze dried products, bottles for infusion, cartridges and non-pvc bags for infusion. The Facilities are divided in : General, Penicillanic, Cephalosporanic, High Activity and Cytostatics. For more information, please visit

Noventure is a Spanish company based in Barcelona, specialized in licensing innovative substance-based medical devices and specialized food supplements. We offer approved medical devices under CE Mark ready for marketing in UE as well as in other territories around the World, and high standard food supplements supporting physiological functions in Gastroenterology, Urogynaecology, Paediatrics & Dermatology areas. Our innovative, substance‐based medical devices are a friendlier and effective solution for the patient. They have no pharmacological, metabolic, or chemical effect, and they respect physiological functions. Our specialized food supplements come in distinctive galenics, thereby increasing acceptability, adherence, and consumer experience.

Novus Capital specializes in M&A advisory for mid market transactions in Russia, the CIS countries, Ukraine and the Baltic States. Members of our team are professional investment bankers with close to 15 years of experience, who organized and closed a number of prominent transactions on the Russian, Baltic and Ukranian pharmaceutical markets. Our team has successfully advised transactions with the total value of more than USD 2bn, including 620 m in pharmaceutical industry. We specialize in pharmaceutical and technology sectors as well as work in media, logistics and FMCG sectors.

NTC is a B2B company that offers an attractive, high quality and innovative product portfolio in order to meet market demands, mainly in the following areas: Ophthalmology; Gastro Intestinal & Metabolism; Pediatrics; Gynecology & Urology; Respiratory & Allergy;                             


Olainfarm is the leading manufacturer in the chemical and pharmaceutical sector of the Baltic States with almost 45 years of experience. Portfolio contains over 60 FDFs, 25 APIs and more than 20 Intermediates. The key areas of specialization in FDFs include neurology, cardiology, infectology and allergology. Olainfarm has a long-standing technological and know-how advantage in adamantane, quinuclidine and nitrofurane chemistry. Olainfarm owns the controlling stake in the leading Latvian food supplement company Silvanols, has its own chain of pharmacies Latvijas aptieka in Latvia, owns producer of elastic medical products Tonus Elast, medical company Klīnika DiaMed and eco-cosmetics company Kiwi Cosmetics. Olainfarm is certified in accordance with the requirements of the EU GMP for APIs and FDFs, the U.S. cGMP for certain APIs (FDA), TGA for FDFs (Australia), CEP for certain APIs, ISO 14001 Environmental Management System and ISO 17025 Laboratory Management System. Representative offices in Russia, Ukraine, Belarus, Tajikistan, Albania, Armenia, Kazakhstan, Kosovo, Mongolia and Uzbekistan, subsidiaries in Russia, Lithuania, Turkey, Azerbaijan and Kyrgyzstan, and contracted agents in the USA, Serbia, Turkmenistan, Moldova, Sweden and Southeast Asia.

Olympe Healthcare is presenting several innovative women health products at PharmaSynergy, if your company would like to expand its business worldwide, let’s meet! We are an international consulting firm offering customized business development services to the Healthcare Industry. Current asset portfolio available for partnering include: A novel painless IUD – CE mark Q4/2020; Diagnostic tests combine with innovative mobile applications (covid19 tests and POC tests); Niche generics & OTC; Premium food supplements

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion’s pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory diseases for which Orion develops inhaled Easyhaler® pulmonary drugs.Orion’s customers are mainly healthcare service providers and professionals such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centres, clinics and laboratories. Consumers with pets are another important customer group. Orion’s main market is Finland, where it is the clear market leader. Orion’s products are marketed in over a hundred countries, and the Group’s own human pharmaceuticals sales organisation covers almost all European markets. In other markets Orion’s products are sold by several collaboration partners. All of Orion’s manufacturing plants and most of its R&D operations are in Finland. Orion’s headquarters are in Espoo.Orion’s A and B shares are listed on Nasdaq Helsinki.

Verman is an independent Finnish company focusing on high-quality products that are promoting health and well-being. Our expertise is in innovation, R&D and marketing and sales. Our main business areas are: Food Supplements; Medical Devices; OTC Pharmaceuticals; Rx Pharmaceuticals. During the past few years Verman has been one of the fastest growing pharmaceutical companies in Finland. Several of our products are market leaders in their product categories. Verman has established its leading position by working in close co-operation with key opinion leaders and customers.


PannonPharma Ltd is a family owned Hungarian company, established in 1994, with Rx and OTC product portfolio of mature branded generics, traditional herbal medicines as well as medical devices in various therapeutic areas and cosmetics. At present the company has more than 70 registered products and several more under registration. It is a fully integrated company with R&D, production, marketing, sales and distribution. Pannonpharma possesses GMP and ISO 9001, ISO 13485, ISO 14001  certificates, and maintains GLP conditions . Apart from manufacturing pharmaceutical products, PannonPharma Ltd also provides continuous support for regional, national and international knowledge centres and research laboratories and it is involved in close cooperation with various universities, and supports realization of patents originating from basic research. Furthermore, PannonPharma’s subsidiary RIMPH (Research Institute for Medicinal Plants and Herbs) offers Concentrate of Poppy Straw, Poppy Straw Extracts (CPS AMA and CPS ATA) and APIs from controlled cultivation and herbal extracts, inclusive Supercritical Fluid Extracts. Our SCF extraction plant has been installed recently, and we have already almost 200 different extraction methods, related to herbal substances of flora of Hungary. The vertically integrated company from medicinal plant research to finished products has been operating in compliance with Good Agricultural and Cellection Practices (GACP).                            


Pharmactive is one of the top ten Pharma producers in Turkish pharma industry; also developper and marketer. The company has around 1000 employers and has a state-of-the-art facility located in Turkey; which is capable of solid, semi-solid and non-sterile liquid production. Annual capacity is 330 M boxes. Pharmactive today exporting its own formulations close to 20 countries including Europe and Middle East; its facility has European and Russian GMP approvals. Pharmactive is open for variable cooperation models; such as; contract manufacturing at its modern facility; codevelopment with its dedicated and well experienced R&D and project management team; inlicensing opportunities for its portfolio in Turkish market

PharmaLinea develops and manufactures clinically substantiated, premium dietary supplements for outlicensing (private label), along with a service unique to the industry. Our clients achieve successful sales because we provide them with a competitive advantage and ensure all they have to focus on is the B2C segment. Some of of our long-term partners are the no. 1 OTC company in Switzerland, the no.1 dietary supplement company in Romania, one of the top 3 Spanish urology companies etc. We are one of the 15 leading companies that comprise the Vitafoods Steering Committee and recipients of several awards for product organoleptics.                           


Since we first opened our doors in 2013, we have focused single-mindedly on delivering high-quality branded prescription medicines to patients, prescribers and healthcare providers across the globe. We specialise in the late-stage activities of development, co-development, licensing and acquisition.

Within our strategic therapeutic areas, we have developed our own innovative medicines as well as niche speciality products, and we have acquired tried and trusted medicines and iconic brands from innovator pharma companies and breathed new life into them.

From a single office in Basildon, we have grown consistently year on year. This has enabled us to reinvest in our products, our brands, our people, and to give back to our communities.

Our goal is to be an agile and imaginative global specialty pharma business and a preferred partner for innovator pharma companies.



PharmaS is a regional SEE company with activities on Rx and CHC areas. We are interesting for in license innovative Rx&OTC drugs and out-licensing our CHC portfolio.                   


Pharmathen UK Ltd #Pharmathen is focused on developing complex pharmaceuticals designed to improve patient compliance. Founded in 1969, Pharmathen has grown to become one of the largest, vertically integrated developers of innovative complex drug delivery technologies and generics molecules. The company identifies and develops its own pipeline, owns its IP, and through long term contracts, out-licenses this IP to customers who in turn market and sell the products. Pharmathen’s products have been licensed and approved in more than 90 countries and sold to over 230 companies worldwide, throughout Europe, United States, Canada, the Middle East, LATAM, Asia, Australasia and Southern Africa. Building on a portfolio of over 100 products, today Pharmathen is working on one of the most extensive and advanced pipelines in Long Acting Injectables, Sustained Release formulations, and Preservative Free Ophthalmics, produced in its FDA and EU approved facilities.


Pharmax Pharmaceuticals FZ-LLC located in Dubai Science Park free zone has been established to develop, manufacture and market branded generic pharmaceutical products. UAE Ministry of Health and Prevention has granted GMP certificate for manufacturing of solid dosage forms and secondary packaging of other dosage forms such as parenterals, inhalers and semi solids. Company is seeking partnerships, strategic alliance, technology transfers and contract manufacturing proposals from interested players.                            


Pharmazac is a Privately-owned company, established in 1986 initially focusing in the Distribution of Pharmaceutical products in the areas of CVS, CNS, Oncology, Musculoskeletal and Food Supplements. Having established itself as a reliable local distributor, Pharmazac signed strategic partnerships as exclusive Partner of multinational companies like Takeda and GE Healthcare. 2016 was a year of reformulation and Pharmazac’s focus shifted in developing, manufacturing, marketing and Licensing Out its own generic products. As such Pharmazac invested heavily in both, state of the art R&D facilities and, attracting industry experts to help in this new strategic repositioning. In parallel, Pharmazac invested in upgrading all necessary infrastructure needed to support the R&D project. Significant investment and resources were allocated to upgrade the RA, Supply/Chain and Business Development & Licensing departments. By the end of 2021, Pharmazac aims at having finalized 11 new product developments fully developed in its own R&D facilities                            


PharmExtracta S.p.A operates in an innovative way in the pharmaceutical and nutraceutical sector since more than 30 years. The unique knowledge in the Phytotherapy, Probiotic and Nutraceutical fields of the R&D department merged with constant communication with the doctor creates formulations that today represent the most innovative solutions on the market in compliance with needs of both the patient and for the clinician. PharmExtracta S.p.A presents a pipeline of innovative products with a rational state-of-the-art formulation, obtained by optimizing the raw materials used and based on the latest scientific discoveries. All products are validated by clinical studies published in the most important journals in the sector. Continuous research, constant dialogue with the doctors and the healthcare stakeholders drive alongside to make PharmExtracta S.p.A a contemporary company to the future.



PharmInterTrade Srl it’s based on a new company concept: to Represent the Business Development Department World Wide of a selected group of small & medium sized Pharmaceutical Company.
Our expertise in Pharmaceuticals and in their International Development, can give us the opportunity to select new partners, choose the right kind of agreement, follow the process from the budgetting, positioning, launch, to the product stock at the manufacturer site and in the distribution channel, like an own internal DPT of each of our Partners.
In other words, “Competence: The single Pharma Success depend on the best skill that we are able to build, in this changing years.”                             


PharOS is a privately owned pharmaceutical company, developing, manufacturing and supplying Generic, Over the Counter and Value Added Medicines with a global portfolio of more than 72 products and over 7.400 marketing authorizations worldwide. Our aim is to provide affordable, high-quality medicines that improve the lives of patients worldwide and satisfy our corporate customers’ needs from product development to launch. Our mission is to materialize in the most effective way our customers trust by ensuring that our products will be among the first to enter the market, following patent expiry, and the last ones to exit. Further to the in-house manufacturing, we embrace the collaboration with well-established manufacturers of finished goods and therefore closely cooperate with strategically selected partners to design, validate, manufacture and market release our products.


Pizeta Pharma S.p.A. is a pharmaceutical company established in 2010 in Perugia, in the center of Italy. It aims to formulate, produce and patent, through its research and development activities, innovative and high quality therapeutic solutions for human’s health and well-being, mainly in nutraceutical area. We closely collaborate with our business partners and with universities with the aim to develop new products and formulations for national and international market. Pizeta Pharma SpA has the quality system certification DNV-GL ISO 9001:2015 and it’s able to guarantee all best service and collaboration for a winwin partnership with clients. WE OFFER Finished product to sell abroad in gynecological, ophthalmological, cardiovascular, pediatric and dermatological areas. Our pipeline of products contains Medical Devices (Class IIA), food supplements and dermocosmetics. we have innovative products with patented formulations and our partner will have the possibility to customize our therapeutic solutions with their brand, our FDF have high quality MADE IN ITALY . WE ARE INTERESTED IN Licensing-Out our references. Innovative formulations in Ophthalmological and Gynecological area, Medical Device “ready to market”. WE ARE NOT INTERESTED IN: Drugs, API, Manufacturer of drug, Oncology and respiratory therapeutic areas.                             


PrecisionBiotics (PB) is an innovative Irish healthcare company and a global pioneer in discovery, development and commercialisation of proprietary probiotic and pharmabiotic treatments. Our new and breakthrough scientific research is recognised around the world as being at the cutting edge of discovery and application. Alimentary Health, the research function of PB, is the foundation industry partner of the Alimentary Pharmabiotic Centre based at University College Cork, Ireland.                             


ProBiotix Health Ltd is a division of the UK-based and London Stock traded Optibiotix (AIM: OPTI) focused on commercializing clinically validated nutraceuticals for Cardiovascular Disease on a global scale. 50% of all deaths in Europe and the US are caused by some kind of cardiovascular disease and 80% are believed to be preventable. We have developed the patented CholBiome® portfolio with EFSA Health claims, human clinical studies, 2-year stab. studies acc. to ICH standards and leading probiotic players like Seed Health, Actial Farmaceutici, and Alfa Sigma have incorporated our patented probiotic technology in their finished products.                   


PromoPharma is a Pharmaceutical company established in Greece in 2007. It counts an impressive sales force of 135 Medical Advisors and it is currently a partner of some of the biggest multinational pharmaceutical companies globally such as Boehringer Ingelheim, Merck, Sanofi, Leo and others



Protina is a medium-sized, family-owned company specialised in the development and GMP-certified production of mineral supplements exclusively in Germany. With leading domestic OTC brands Basica® and Magnesium Diasporal®, its portfolio includes a range of OTC drugs and food supplements. One third of annual turnover is generated from global operations, which the company continuously expands.                             


Qualiphar is a 100% family owned company specialized in the development, production and marketing of OTC healthcare products.  Active in Belgium and France with own sales & marketing teams, and outside these home-countries through well-established local partners. Annual turnover of 80 million € and 400 employees                          


Recipharm are a top 5 CDMO with 30+ development and manufacturing sites worldwide. Besides contract services, Recipharm are offering a new co-development and out-licensing service leveraging our vast development and manufacturing footprint. We look forward to discussing how we can best partner around new product candidates.


Founded in 1929 in Spain, Reig Jofre is a pharmaceutical company listed on the Spanish Stock Exchange market, dedicated to the research, development, manufacture and marketing of pharmaceutical products and food supplements. Reig Jofre has more than 1,100 employees, 4 development and production centers in Europe , direct sales in 7 countries and more than 130 business partners in more than 70 countries around the world. Reig Jofre Specialty Pharmacare Divission has a strong porfolio in osteoarthritis and musculoskeletal pain segment, dermatology and pediatrics, with innovative pharmaceutical products, medical devices and food supplements, all of them very well supported with clinical studies. The products have already a success marketing experience in Spain and other European markets. Reig Jofre is interested in contacting with companies present in osteoarthritis/ musculoskeletal segment, pediatric and dermatology or companies which would like to enter in these areas.


Repha GmbH Biologische Arzneimittel is a medium-sized, family-run and research-based company based in Langenhagen near Hanover, Germany. Founded in 1925, Repha started developing unique herbal remedies. 

Today it is a strong, future-oriented and dynamic family company with a long tradition. With experience and passion, it dedicates itself to our medicinal plants with a focus on unique combinations to help people with acute and chronic illnesses to stay or become healthy. The cultivation of its medicinal plants and the production of the preparations are carried out responsibly and with a high-quality standard (GMP).

Reliability, trust and fairness are important to Repha. They work close with pharmacies, doctors and alternative practitioners, scientists and partners in the healthcare sector. They listen to the users and learn from their experiences with the companies remedies. The preparations (Angocin, Myrrhinil-Intest, Nortase and many more) are used beyond national borders by patients whose well-being determines our daily actions. They are focused on the treatment of infections in the respiratory tract, urinary tract and gastrointestinal diseases. 

Research spirit drives Repha. They promote Germany as a research location. It is their strength to scientifically confirm empirical medicine and to further develop it intensively. That is why they advocate the integration of naturopathy into medical treatment, because they are deeply convinced of its benefits for people.


Ridge Pharma is a privately-owned UK pharmaceutical company established in 2017. Our business is focused on the commercialisation of prescription medicines for unmet needs in the UK market. Using our teams’ collective capabilities, we have successfully launched our first brand, with more products in the pipeline. Our objective is to identify and invest significantly in the marketing and promotion of medicines that require a branded strategy that will provide long term value for Ridge and our licencing partners. We also look for partner companies that wish to use our platform to launch generic products into the UK market, driving revenue for both parties.                             


RIEMSER Pharma GmbH is part of the Esteve group. ESTEVE is a leading private pharmaceutical chemical group headquartered in Spain, with direct presence in Spain, Germany, France and UK and a widespread international partner network.  The focus of the joint company is on niche therapy areas with high unmet medical need and our proprietary product portfolio distributed worldwide. We are looking We are interested to in-license late stage specialty products, including CNS, Ophthalmology, Onco and other niche areas with emphasis in fast time to market assets and we are looking to new partners interested to distribute our products outside Germany, France, Spain and the UK. We are a partnership-oriented company and we offer substantial expertise and successful experiences in our strategic alliances.                                  


Rosemont Pharmaceuticals is dedicated to the development, manufacture and supply of Rx Oral Liquid Medicines for patients that have difficulty in swallowing solid medications or those who need a precisely measured dose not available in a solid formulation. With over 50 years’ dedicated experience Rosemont are the world leading specialist in Rx Oral Liquids and currently manufacture and supply over 150 products in most therapeutic areas including Cardiovascular, CNS, Endocrine, Gastrointestinal, Malignant disease and Immunosuppression and Infections, Musculoskeletal and Joint Disease, Nutrition & Blood. Eight products of our UK range are licensed for use with PEG/NG tubes.           


R-Pharm – Russian high-tech pharmaceutical enterprise, successfully transformed from distribution to a fully vertically integrated specialty pharma player. Key areas of R-Pharm’s competence include: manufacturing of finished drugs and APIs, R&D of innovative medicines and technologies, training and education for industry and health care specialists, venture investments in promising scientific data and research, cooperation with major international pharmaceutical companies and international universities in the field of drug development and combined clinical trials in Russia. Since foundation not less than 85% of profits reinvested into infrastructure and products development.                             


SAJA is a joint venture between the premier Saudi healthcare company Tamer Industries and two of the leading Japanese pharmaceutical companies which are Daiichi Sankyo Company Ltd and Astellas Pharma Inc.


Salix is an Italian development and contract manufacturing organization with know-how and production capability for food supplements. medicated foods, medical devices. Beside customized formulas and products, Salix has also its own portfolio of food supplements and medical devices as well as propetary technology suitable for medicated foods.

We share a deep commitment to service and customer service, which, combined with our professionalism, helps us achieve our primary objective: giving a longer, healthier, happier life to society by offering safe and efficacious drugs. We are able to achieve this goal through research and analysis, as well as an understanding of the needs of our patients, professionals, distributors and institutional representatives.                            


Sandoz GmbH # Sandoz is a global leader in generic pharmaceuticals and biosimilars and a division of the Novartis Group. Our mission is to discover new ways to improve and extend people’s lives. Sandoz contributes to society’s ability to support growing healthcare needs by pioneering novel approaches to help people around the world access high-quality medicine. That is our purpose. Our global portfolio comprises approximately 1 000 molecules, covering all major therapeutic areas, which accounted around USD 10 billion. Our broad offering translates into substantial and ongoing savings for patients and payers, which help to ensure the sustainability of healthcare systems in the face of significant budgetary pressures, while also freeing up funding for innovative medicines. Our products reach more than 500 million patients and our aspiration is to reach one billion. Our broad portfolio is spearheaded by our global leadership position in both biosimilars, the “cutting edge” of innovative off-patent medicines, and generic antibiotics, the foundation of global healthcare systems. We also run a broad range of targeted corporate responsibility programs to increase access to medicine, medical information and appropriate medical training for healthcare professionals. Sandoz B2B is a division within Sandoz that offers API and finished products to third party customers globally, which accounts approximately USD 600 million. We are headquartered in Austria, leading supplier of anti-infective products worldwide and would like to explore opportunities globally for APls and finished products among those 1000 molecules, which we can discuss on case-by-case basis.                    


Sanofi is a global life sciences company committed to improving access to healthcare and supporting the people we serve throughout the continuum of care. From prevention to treatment, Sanofi transforms scientific innovation into healthcare solutions, in human vaccines, rare diseases, multiple sclerosis, oncology, immunology, infectious diseases, diabetes and cardiovascular solutions and consumer healthcare.


Saval is a Chilean company with subsidiaries in South – and Central America. Its Headquarter and facilities are located in Santiago de Chile. Saval is present with branded generics in different therapeutic areas in retail (ophthalmology, respiratory, infection, pediatrics, gastroenterology, cardiology, metabolic diseases) and also in the hospital range (biosimilars in AR and oncology ). Over the years Saval established successfully different partnerships with other companies, such as MSD, Bayer, Pfizer, Lilly, Celltrion and others. We are constantly looking for new assets for licensing-in, both for prescription drugs in the retail area and especially also for assets to restrengthen our younger hospital range.



Seltfar – Seltfar

Seltfar LTD is a privately held pharmaceutical company specialized in the promotion and distribution of pharmaceutical products, MD, and FS in the Republic of Kazakhstan, Uzbekistan, and Belarus.



Global Boutique Business Development (M&A) Advisory Firm with $13.5B in management transaction experience.                             


Henlius is a leading biopharmaceutical company in China with the vision to offer high-quality, affordable and innovative biologics for patients worldwide with a focus on oncology and autoimmune diseases. Starting from biosimilar, Henlius presses forward with novel mAb products and immuno-oncology combination therapies with proprietary anti-PD-1 and PD-L1 mAbs as backbone. We are attending PharmaSynergy mainly to: (1) Out License our products; (2) In License innovative onco programs; (3) Implement R&D and Clinical Collaboration on Onco programs; (4) In License innovative Onco Finished Products for Chinese market.



Shenzhen Beimei Pharmaceutical Co. Ltd. is a well-established, innovation-driven specialty company focused on pediatric prescription medicines in China. We are committed to offering competitive products and services to meet China’s unmet medical needs.



Laboratorios Silanes, S.A. De C.V. was founded in 1946. The Company’s line of business includes the manufacturing, fabricating, or processing of drugs in pharmaceutical preparations for human or veterinary use.



Singapore Biotech is a trusted biosimilar company that changes lives by making advanced biologics more accessible and more affordable. The EU-GMP certified manufacturing facilities enable us to deliver world-class quality biosimilars to patients, across the globe. Utilizing the latest manufacturing technologies, we support our international partners to increase uptake of biosimilars in different regions. Singapore Biotech currently markets 13 biosmilars in various emerging markets, offering access to high quality medicine to over one million patients with serious and rare diseases. Singapore Biotech’s continuous growth is backed by a rich pipeline of 16 molecules covering diverse therapeutic areas in debilitating diseases affecting millions of patients around the world. Research and development activities account for over 20% of our annual revenues. As a full-cycle manufacturer we have developed our own effective methodology and know-how from upstream to downstream processes, enabling us to produce affordable and quality biosimilars                            


Polski producent leków – S-Lab

S-LAB is a pharmaceutical company focused on the production of innovative products in two areas: Ophthalmology and cold remedies. We have our own sterile facility for the production of multi-dose eye drops without preservatives, sterile ointments and sterile wet wipes and throat pain lozenges. We offer ready to launch products with the Medical Device certification. We are looking for exclusive distributors for our innovative ophthalmic and throat pain lozenges.                      


So.Se.PHARM SRL, established in 1978, is the marketing authorisation holder specialist within the family owned Pharmaceutical Industrial Group with headquarters and manufacturing plant in Anagni (Frosinone), Italy. The Company directly supplies Hospitals, Clinics and other (both private and public) Health Organizations. Moreover, the firm has scientific and technical advertisers/representatives who constantly improve their know-how by turning to updated information concerning materials, methods and appliances, and by contacting general practitioners and/or specialist physicians in the market of Italy. The Export Department develops synergic relationships with foreign partners (importers, distributors and/or other pharmaceutical companies) in order to meet the reciprocal needs and to expand the presence of So.Se.PHARM SRL and of the plant in the local export markets. The factory produces pharmaceutical specialties for So.Se.PHARM SRL and for the market of the generic ones. The plant Special Product’s Line Spa (Anagni) is authorised in the manufacture of not sterile products:  rigid capsules, liquids for internal use (also suspension of bacillus Clausii spores, other solid pharmaceutical forms (granules), semisolids special requisites: hormones or substances with hormonal activity (also corticosteroids hormones), suppositories, tablets and production of API by fermentation (bacillus Clausii spores). The plant is authorised and well equipped for production of effervescent tablets into tubes and into blisters and in the production of stick packs as liquids and granules in variable dimensions. At present we do manufacture on behalf of 68 clients and around 530 pharmaceutical forms. Total personnel is 400 persons (variable data).        

SOFAR is a leading Italian pharmaceutical company specialized in Gastroenterology, Gynecology, Urology and Dermatology, with a portfolio of more than 100 products including drugs, dietary supplements and medical devices. In Italy SOFAR has a sales force structure of more than 150 Medical Reps calling on GPs and Specialists. Outside Italy, SOFAR is present with 5 affiliates in USA, Russia, Switzerland, Romania and Lithuania – and 18 distribution partners worldwide. SOFAR works constantly on new products, launching every year up to 5 new products all under SOFAR brand. All products are based on IP, clinical studies, innovation, to guarantee to the market effective HIGH QUALITY on which SOFAR continues to strongly invest. In Europe, markets of interest are: Germany, France, UK, Spain and Nordics. We are looking for partners of choice for our products mainly in Gastro area: GERDOFF (innovative patent protected MD class III for GERD); ENTEROLACTIS range (N.1 probiotic dietary supplement in Italy); MESALAZINE 1200 mg gastro-resistant MR tablets.

SPIMACO is one of the hugest pharmaceutical Co. in Gulf area (GCC)& it’s No. 1 pharmaceutical firm in Private market of Saudi Arabia, with current presence in 14 countries in the MENA region. SPIMACO established in 1986, it’s the only Saudi Pharmaceutical Company listed and quoted in the Saudi Stock Market. SPIMACO Total 2018 sales were SR 1.3 billion (almost USD 430 Mio). SPIMACO is enjoying longlasting collaborations with major MNCs, in extremely successful projects represent various models of partnership including: comarketing, co-promotion, contract manufacturing,licensing-in, licensing-out, products acquisition, products divest, and distribution. SPIMACO enjoys the reputation of being the partner of choice in the Saudi & GCC markets. Our current major alliances include: (Lilly, GSK, Sanofi, MSD, Pfizer, Novartis, Roche, Vifor, and many others).                    

STADA is your partner of choice for generics, specialties and consumer health with above 10,000 employees selling its products in more than 120 countries with main focus on Germany, Central Europe, CIS/Eastern Europe, Asia&Pacific, MENA. STADA’s headquarter is based in Bad Vilbel, Germany, close to Frankfurt/Main. STADA’s core segments are generics (Rx and OTC), which represent about 60% of group sales, and branded products (OTC and Rx specialty pharmaceuticals), which represent 40% of group sales. STADA develops, manufactures and markets pharmaceutical products with a long experience in R&D as well as in regulatory issues, notably European regulatory procedures.                  


SteriMax is a specialty pharmaceutical company. It develops, sources, manufactures, markets and distributes essential hospital and retail pharmacy products to the Canadian healthcare market. SteriMax has successfully added an array of parenteral products, establishing a formidable portfolio of products that are essential for the Canadian Hospital market. Despite our strength in Sterile Injectable products, we have also found unmet needs and opportunity within niche oral solid, nasal spray and ophthalmic products and these have served to expand our presence in the Canadian Retail pharmaceutical sector. We have built a team of talented and dedicated people and have in-house expertise in all functional areas. Extensive Technical, Regulatory and Quality departments augment a Commercial team that makes SteriMax a Canadian partner of                  


Established since 1993 based in Watford, Strides Pharma UK Ltd has been driven by our core values, Reliability, Quality and Value. We pride ourselves in commitment to putting patient care, safety and the forefront of our mission is to become one of the leading UK manufacturers of medicinestrides Pharma UK Ltd          

Sumitomo Corporation is a Fortune 100, global business conglomerate with diversified business interests and headquartered in Tokyo, Japan. Our Life Science business is into generics business in USA and we are looking for in licensing and co development opportunities for our group company Upsher-Smith Laboratories, USA and dossier trading opportunities for our USA office Sumitomo Corporation of Americas.                 


Symphar is a Polish pharmaceutical company with our own branded generics RX/OTC (licensing-in and licensing-out), food supplements, medical devices, diagnostic tools and we import and distribute selected international brands.                             


Synthon is a fully integrated company focusing on the development and out-licensing of generics with strong expertise in R&D, IP and Regulatory Affairs. Synthon is developing a wide range of products with a clear and committed focus on products with a technical-, legal- or IP-barrier, especially in the CNS- and oncology area. Synthon’s head offices are based in the Netherlands. R&D, API, Bulk product and Finished packed product production and sales locations are further found in Spain, Czech Republic, Argentina and Chile.                       


Tabuk Pharmaceuticals develops, manufactures, markets and distributes branded generic pharmaceuticals and under-licensed products globally, with a strong focus on the Middle East and North Africa region. Since its foundation in 1994, Tabuk has passed several milestones in its journey towards becoming a successful player in the global branded generics pharmaceutical industry. Headquartered in Riyadh, Saudi Arabia, the company has strong presence across the Middle East and North Africa (MENA). Today, Tabuk is the second largest Saudi pharmaceutical manufacturer and one of the top five in sales in the Kingdom of Saudi Arabia. TABUK is among the few companies in the Middle East that can manufacture oral as well as sterile Cephalosporin antibiotics.                            


Tamer Group began as the first pharmacy in the Kingdom of Saudi Arabia, established by the late Dr. Mohammed Said Tamer in 1922. Today Tamer Group is a leading healthcare, beauty care, prestige products, and fast-moving consumer goods company responding to the growing needs of the Saudi and Middle East communities. The Group’s core activities are import, distribution, promotion, marketing, and manufacturing. Today, Tamer Group has established a special position in the Saudi marketplace, resulting from a unique approach to business, service, and customer portfolio.   Headquartered in Jeddah, Saudi Arabia, Tamer Group serves many of the world’s leading companies through various agreements, partnerships, and joint ventures.                      


TannerMedico A/S is a Scandinavian company founded in 2005 with corporate headquarters located North of Copenhagen in the DTU Science Park. TannerMedico A/S is the manufacturer of the Anti-snoring brand Asonor® – one of the world’s leading anti-snoring preparations. The production facilities are located in EU and our products are manufactured under pharmaceutical control and in GMP regulated production facilities.  Our mission is to help people suffering from heavy snoring to a relief of the problem and turn the night into a positive part of the everyday. Undisturbed and restorative sleep is vital for the health. 

Asonor® is an advanced nasal solution with a patented delivery system that ensures the solution to reach the throat where the effect to eliminate the cause of snoring takes place.

Asonor® is an effective treatment of heavy snoring and is an award-winning formula.


Techdow Pharma Spain is dedicated to providing quality and cost-effective therapeutic solutions for the prophylaxis of Venous Thromboembolism (VTE) and the treatment of Deep Venous Thrombosis (DVT).  
Focused on growth through the introduction of new products and services, Techdow will use collaborations and strategic alliances that help identify and implement new solutions for the Spanish market and the international market.



Tecnimede – Sociedade Tecnico Medicinal, S.A. With a strong position in generics market and a clear orientation to quality and technological innovation, the R&D is a key factor in our development strategy. With a portfolio of over 100 generic medicines registered worldwide we offer EU CTD dossiers, manufacturing analytical services for batch release.                         


Teriak (Kilani Group) #Teriak is a Subisdiary of Kilani Group. Teriak has 2 sites in Tunisia (one site dedicated to DPI-injectables-fill and finish of biosimilars, and the second site is dedicated to all dry forms (sachets, pills, tabs, capsules, liquids (sachets, bottles), cream and ointments), one site in Cameroon and Cote d’Ivoire (both for beta lactames (separate site), dry forms, liquid forms) Teriak has its extended range of generics and manufactures and distributes underlicenced products of Novartis, GSK, Servier, Abbott. Teriak (through its four sites) manufactures, distrbutes and exports in North Africa (Tunisia and Libya) and French subsaharan countries with its dedicated field force. Teriak is interested in partnering – for biosimilars, injectables, DPI, generics – licensing In and Licensing out – contract manufacturing for european countries                       


We are one of the UK’s fastest-growing, leading producers of OTC healthcare and household products, and own some of the country’s most loved brands such as Covonia®, Hedrin®, Cetraben® as well as the leading disinfectant Zoflora®.   


Unolab is a Contract Manufacturing Laboratory for sterile monodose products. We manufacture single dose vials for small volumes since 0,4 mL up to 10 mL. We offer the most advance technology in the market, Blow Fill and Seal from Rommelag. We work under ISO 13845 and GMPs certifications. We offer a full service experience for our clients, since the R&D of the formula, formulation of the product, dosification, sterile manufacturing and packaging. We count with an experienced team of Project Mangers that will listen into our clients needs and will provide the needed solution. We are experts in the development of medicaments, medical devices, food supplement and different proposals in the field of sterile dosification. Unolab is also the owner of a portfolio of Medical Devices under our CE Mark for respiratory and ophthalmology purposes. For any further information, please do not hesitate to contact us for our portfolio.


Velit is part of a Group including 3 companies. 

Velit Bioharma = Development& Licensing in-out international

Nanovector = R&D in nano-microlipids

Sintesi Pharma= Marketing& Sales of Generics in Italy

Taking care of our customers and their patients, all over the world, is Velit major challenge. Our effort lies in developping difficult products and in offering them, under private label, to pharmaceutical companies and distributors.

Focal segments are: Peptides/Biopharmaceuticals ‚ Nano-pharmaceuticals ‚ Oncology ‚Patches ‚ Oral disintegrating film (ODF)                         


VIANEX S.A. was established in 1924 and has 90 years of experience in the pharmaceutical field having demonstrated exceptional business achievements in a wide range of activities such as manufacturing, licensing, marketing, exporting and distribution of pharmaceutical products. VIANEX S.A. is the leading pharmaceutical company in Greece with 5,3% of the total Greek pharmaceutical market in ex-factory prices for the products we represent in Greece. It also covers 25% of the total pharmaceutical production in units. VIANEX S.A. consists of 1.050 employees, 510 of them working as salesmen and marketers. The company has an excellent distribution department and distributes the products of each firm that represents to all State Hospitals (150), all pharmaceutical wholesalers (110) and all pharmaceutical cooperatives. VIANEX S.A., having four (4) state-of-art fully specialized Manufacturing Plants guarantees outstanding production capabilities. The company covers the entire spectrum of manufacturing activities while it continuously upgrades the range of services. The aim of VIANEX SA is to provide Pharmaceutical Companies, not present in the region, with a network of professional Sales, Marketing, Regulatory and Medical Services in specific therapeutic areas in which we have proven expertise and which form a part of our future strategic objectives. During the last decades, VIANEX S.A. has established successfully partnerships with well-known Pharmaceutical Firms worldwide based on varied distinct Licensees as well as distribution and contract Manufacturing Agreements. A key factor of our growth is the successful and long lasting relations with firms of international reputation that are our partners: Merck & Co (USA), Sanofi Pasteur MSD, Sigma Tau (Italy), Glaxo, Takeda etc. VIANEX S.A. is fully harmonized with EU regulations. VIANEX S.A. has been inspected and approved by different Health Authorities: Japanese, GCC countries, MENA region and Turkish Health Authorities…                           


VIATRIS™ is a new kind of global healthcare company formed in 2020 through the combination of Mylan and Upjohn, a legacy division of Pfizer. By integrating the strengths of these two companies, including our global workforce of approximately ~45,000, we aim to deliver increased access to affordable, quality medicines for patients worldwide, regardless of geography or circumstance. Our unique capabilities, commitment and vision position us to help meet the world’s evolving healthcare needs through access, leadership and partnership. As we work to help patients live healthier at every stage of life, we continue to advance responsible and sustainable operations, recognizing that our actions affect the stakeholders and communities we serve.  

 Our global portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized iconic brands, generic, complex generic and branded medicines, a growing portfolio of biosimilars, and a variety of over-the-counter consumer products.     

  As the world’s healthcare needs evolve, our Global Healthcare Gateway™ offers partners ready access to expanded markets through an innovative global infrastructure that connects people around the world to high quality medicines and services they need.           


Welding GMbH & Co. KG is a privately owned company founded 1955 in Hamburg, Germany with a subsidiary in Lyon, France. Continuity and professionalism are reflected by more than 120 employees. Our core competences are the development, registration, and licensing of generic formulations. Welding tackles the challenges of the global pharmaceutical market with fully fledged development packages for its generic products. Starting from API sourcing or even from the development of API syntheses, IP researches, regulatory affairs coordination, launch support and supply chain management. In addition, Welding understands its role as a first choice partner for global marketing, sourcing, and distribution of active pharmaceutical ingredients. Services EU-Marketing Authorisations and / or Registration Dossiers in EU-CTD format for generic pharmaceutical products and development projects; US ANDA’s and / or Registration Dossiers in eCTD format for generic pharmaceutical products and development projects for the US market; An international network for Marketing Cooperation of dossiers and late stage developments; API supply and contract synthesis/ manufacturing services for the generic industry. A complete list of our projects can be provided upon request in advance of the meeting in electronic format. We are interested in: • Out-licensing of formulation developments • Contacts with potential cooperation partners for API and generic formulation developments • Marketing Cooperation possibilities                           


Xbrane Biopharma AB is a Swedish clinical stage biotech developing biosimilars in the field of immunology and oncology. Being the first and only biosimilar player in the Nordic region, Xbrane levarages its proprietary protein expression technology platform ”LEMO” and its expertise in protein engineering to create the most favorable COGS for large scale protein production through a well-balanced yield and quality of target protein in the E. Coli expression system.                 


URiA-PHARM LLC Biopharmaceutical corporation, among TOP 5 manufacturers in Ukraine and CIS with 3 manufacturing sites (in Ukraine and Italy), 12 offices worldwide and multinational team of almost 3000 people. The leader in hospital procurement and supply with main focus on blood and plasma substitute solutions, original infusion drugs, antibiotics, fungicidal drugs, syrups, antiseptics, parenteral nourishment preparations, anti-tuberculosis drugs, nebulizer systems, varied portfolio of means of administration and products with cross-linked and non-cross-linked hyaluronic acid. The company has own R&D centers, including the newest one for biotech products, is open to innovative LICENSING-IN opportunities as well as to LICENSING-OUT of ready-to-use products and R&D assets in biotech and pharma. Our effort lies in developping difficult products and in offering them, under private label, to pharmaceuticals companies and distributors.    


We have placed the B2B business at the heart of our growth plan. We are cost leader in Urology, Cardiology, Oncology and Pain products and we specialise in Hormones, Steriles, and Pellet technologies. We have our own development and competitive, high-quality manufacturing facilities. We demonstrate a high operational intensity, transfer over 80 products per year and benefit from a global regulatory experience.

– Out-Licensing to scale volumes

– Co-development to share investments

– Life Cycle Management to stay sustainable

– Contract manufacturing

– Export from Europe to scale up volumes

– Private label to develop customers


Zentiva is a producer of high-quality affordable medicines serving patients in Europe and beyond. With a dedicated team of more than 3,000 people and a network of production sites – including flagship sites in Prague and Bucharest – Zentiva strives to be the champion of branded and generic medicines in Europe to better support people’s daily healthcare needs. We are extending to CIS and Russia.Our effort lies in developping difficult products and in offering them, under private label, to pharmaceuticals companies and distributors. Our broad product portfolio covers the main therapeutic areas. Our key product groups include anti-infectives and medicines for cardiovascular disease, pain, central nervous system disorders and gastrointestinal disease. At Zentiva it is our aspiration that healthcare should be a right and not a privilege. More than ever, people need better access to high quality affordable medicines and healthcare. We work in partnership with physicians, pharmacists, wholesalers, regulators and governments to provide the everyday solutions that we all depend on.